Mouth-as-a-Platform

Part
01
of fourteen
Part
01

GSK Initiatives

GSK has released drug remedies for COPD, malaria, meningitis, cancer, anemia, and lupus. They are partnering with 23andMe to pursue genetic studies and discoveries.

PRESS RELEASES FROM GSK- LAST TWELVE MONTHS

Trelegy Ellipta — Japan- May 29, 2018

  • An application has been submitted.
  • Trelegy Ellipta is a"once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD"
  • Japan currently has no triple therapy like this.

Bexsero- Europe- June 27, 2018

  • Infants can now be protected against meningitis in fewer doses with an alternative 2+1 dosing schedule instead of the 3+1 schedule.
  • Bexsero is given in two doses, followed by a booster. Two months must pass between the first and second dose.
  • They hope the reduced doses will improve compliance.

Krintafel- July 20, 2018

  • Krintafel is a malaria cure that was approved by the FDA.
  • It is in collaboration with Medicines for Malaria (MMV).
  • It is indicated for patients age 16 and over.
  • "Krintafel is an 8-aminoquinoline derivative with activity against all stages of the P. vivax life cycle, including hypnozoites".
  • It is not approved anywhere else in the world, but submissions to Australia have been made.

Partnership With Adaptimmune for T-Cell Therapy (GSK-794)- July 24, 2018

  • This therapy is the first one to show a response with solid tumors.
  • "GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognising with high affinity the tumour-specific antigen, NY-ESO. When the modified cells are re-infused into the patient, they recognize and kill tumour cells that express the NY-ESO antigen".
  • "NY-ESO is expressed at various levels across different tumours, and appears to be expressed at high levels in defined sub-types of soft tissue sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers".

GSK Signs Agreement with 23andMe- July 25, 2018

  • They will be working together to use genetic insights to develop new novel medicines.
  • The four-year agreement will focus on discovering new cures using genetics as the "basis of discovery".

Kozenis- Australia- September 21, 2018

Mepolizumab For COPD- September 7, 2018

  • GSK did not get approval for Mepolizumab for COPD, as the FDA needs more clinical data that it is an effective add-on treatment to "inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD), guided by blood eosinophil counts."
  • GSK will work with the FDA to determine next steps.

Trelegy Ellipta - Europe- November9, 2018

  • The drug has gained expanded COPD indications.
  • It is a once-daily, single inhaler, triple therapy.

Daprodustat in Japan- November 22, 2018

  • This is a potential new treatment for "anemia associate with chronic kidney disease".
  • GSK has partnered with Kyowa Hakko Kirin.
  • "We anticipate making a regulatory submission to the Japanese Ministry of Health, Labour and Welfare in 2019 and if approved, we believe daprodustat would be an important new oral treatment option for Japanese patients with anaemia associated with CK".
  • "Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the production of red blood cells and iron metabolism, similar to the physiological effects that occur in the body at high altitude".

GSK & Merk Jointly Develop Bintrafusp Alfa- February 5, 2019

  • It is an immunotheraphy for difficult to treat cancers.
  • "M7824 is an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers".
  • "This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC)."

Dovato by ViiV- April 8, 2019

  • Dovato has been approved as a "once daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults".
  • In Gemini trials the drug was studied for 48 weeks with no cases of resistance.
  • "Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen".
  • Several other submissions are planned for 2019. It is under review by the "European Medicines Agency (EMA) and regulatory authorities in Canada, Australia, Switzerland, and South Africa ".

Benlysta- April 26, 2019

  • Benlysta has received US approval for "intravenous use in children with lupus aged five years and above".
  • This is the first drug approved for children with "systemic lupus erythematosus (SLE)".
  • "The approval extends the current indication in the US for the IV formulation of Benlysta in adults, to patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy".
  • "The IV formulation of Benlysta is currently not approved for use in children anywhere else in the world although regulatory submissions are ongoing in other parts of the world."

Cabotegravir and Rilpivirine Combo Drug- by ViiV- April 29, 2019

  • ViiV submitted an application to the FDA for the "first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV. If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV".
  • ViiV submitted this drug with Pfizer and Shinogi Limited.
  • Injected monthly, it has been proven effective as a viral suppressor in a 48-week study.

Shingrix in China- May 23, 2019

  • Shingrix has been approved in China for the "prevention of shingles in adults age 50 and over".
  • "Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses".
  • China put Shingrix on the list of their urgently needed new medicines and expedited review.
  • The vaccine has 90% efficacy in all age groups.

Nucala (mepolizumab) — June 6, 2019

  • The FDA has approved two new methods for administering "Nucala, and auto-injector and a pre-filled syringe, that is administered every four weeks".
  • It is the "first anti-IL5 biologic to be licensed in the US for home administration".
  • It is the first "respiratory biologic to be approved for administration by an auto-injector".

Zejula (niraparib)- June 24, 2019

  • Tesaro submitted a new drug application for the treatment of "advanced ovarian, fallopian, or primary peritoneal cancer for patients that have been treated with three or more prior chemotherapy regimens".
  • Zejula is an active late line treatment.
  • It is an oral, once daily PARB inhibitor.
  • It is currently being evaluated in three different trials.

CURRENT GSK PRODUCT PIPELINE (06/26/2019)

Detailed information can be accessed here.

Oncology

  • Phase 3: Zejula, dostarlimab,
  • Phase 2: dostarlimab, 2857916- B-cell maturation antigen antibody drug conjugate, 3377794-NY-ESO-1 autologous engineered TCR-T cells (engineered TCR), 3359609- Induced T-cell co-stimulator (ICOS) agonist antibody, molibresib (525762), M7824- Transforming growth factor beta, TSR-022- Anti-T-cell immunoglobulin and mucin domain-3 (TIM-3) antibody
  • Phase 1/2: 3174998- OX40 agonist monoclonal antibody,
  • Phase 1: 3326595- Protein arginine methyltransferase 5 (PRMT5) inhibitor, 1795091- Toll-like receptor 4 (TLR4) agonist, 2636771- Phosphatidylinositol 3-kinase (PI3K) beta inhibitor, 3368715- Protein arginine methyltransferase 1 (PRMT1) inhibitor, 3145095- RIP1 kinase inhibitor, 35371422- NY-ESO-1-targeting bispecific, TSR-033- Anti-lymphocyte activation gene-3 (LAG-3) antibody

HIV/Infectious Drugs

  • Submitted: Dectova, dolutegravir + lamivudine,
  • Phase 3: dolutegravir + lamivudine, fostemsavir, cabotegravir + rilpivirine,
  • Phase 2: cabotegravir, gepotidacin, 32288361- HBV antisense oligonucleotide, 33894041- HBV LICA antisense oligonucleotide, 3640254- HIV maturation inhibitor,
  • Phase 1: 3036656- Leucyl t-RNA synthetase inhibitor, 3810109- HIV broadly neutralizing antibody

Immuno/Inflammation

  • Phase 3: Benlysta + Rituxan,
  • Phase 2: Benlysta + Rituxan, 3196165-Granulocyte macrophage colonystimulating factor monoclonal antibody, 2982772- Receptor-interacting protein 1 (RIP1) kinase inhibitor, 2330811- Oncostatin M (OSM) monoclonal antibody
  • Phase 1: 2831781- Lymphocyte activation gene 3 (LAG3) protein monoclonal antibody, 2983559- Receptor-interacting protein 2 (RIP2) kinase inhibitor, 3358699- BET targeted inhibitor, 3858279-CCL17 inhibitor,

Respiratory

  • Complete Response Letter: mepolizumab
  • Phase 3: mepolizumab, fluticasone furoate + vilanterol + umeclidinium,
  • Phase 2: 2586881- Recombinant human angiotensin converting enzyme 2 (rhACE2), 2862277- Tumour necrosis factor receptor-1 (TNFR1) domain antibody, 3772847- Interleukin 33r (IL33r) monoclonal antibody, 2881078- Selective androgen receptor modulator
  • Phase 1: nemiralisib, 2292767- Phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, 3511294- Interleukin 5 (IL5) long-acting monoclonal antibody,

Vaccines

  • Approved: Shingrix
  • Phase 3: Shingrix, Rotarix, Bexsero, MMR
  • Phase 2: COPD, Hepatitis C, Malaria next generation, Malaria prophylaxis (Plasmodium falciparum), Menveo Liquid, Shigella, Tuberculosis, RSV, HIV,
  • Phase 1/2: RSV, Flu universal,

Other

  • Approved: Krintafel
  • Phase 3: daprodustat
  • Phase 2: oxytocin (inhaled), linerixibat
  • Phase 1: 3439171- Hematopoietic prostaglandin D2 (hPGD2) synthase inhibitor

CURRENT LIST OF NEW PRODUCT DEVELOPMENTS (06/26/2019)

Currently, GSK is seeking input and products in the following categories. They require proof of concept at this stage. The complete list can be viewed at GSK.

  • Barrier Forming Products for upper respiratory tract
  • Antioxidant/Anti-inflammatory products that combat air pollution
  • Digital devices to manage respiratory health
  • Digital health platforms for respiratory conditions
  • Nasal spray deliveries for allergies
  • Next generation nicotine replacement- transdermal
  • Long lasting reflux management
  • Pain relief
  • Lower digestive health solutions

Research Strategy

Relevant information for GSK was taken directly from their press releases and website. Please note, there is a high occurrence of quotation marks due to the detailed medical jargon.
Part
02
of fourteen
Part
02

Competitive Landscape - Pfizer and Merck

After an extensive search of Pfizer's and Merck's press releases and investor relations materials, as well as relevant third-party databases and media sources, no evidence was found linking either company to 'Mouth-as-a-Platform' technologies. As such, we have entered 'N/A' in the relevant cells of the attached spreadsheet. Below are several potentially useful findings regarding these companies' involvement with novel research related to saliva and biomarkers, followed by a thorough explanation of our research methodology.

Findings

  • Pfizer scientists are currently conducting research to determine if, and how, they can leverage extracellular vesicles (EVs), cell secretions that are contained in saliva as well as blood and urine, to gain medical insights about patients.
  • Pfizer is conducting research using the UK Biobank, which includes samples of saliva as well as blood and urine from some 500,000 people, to sequence the exomes (the part of the genome that encodes for proteins) of the participants. One goal is to determine if there are genes that are absent in healthy individuals and could be eliminated in other individuals for therapeutic reasons.
  • Pfizer is linked to research regarding two biomarker-related diagnostic tools, including "a composite application on the Apple iPad for at-home assessment of Alzheimer's disease patients" and Akili Interactive Laboratories' "digital biomarker assessment tool among participants with and without brain amyloidosis, an acknowledged Alzheimer's biomarker," though neither of these devices are related to the mouth.
  • Merck Millipore centrifuges were used in a study regarding "saliva as a medium to detect and measure biomarkers related to pain."
  • Similarly, a Merck Millipore centrifuge was utilized in a study measuring "8-hydroxyguanine as an oxidative stress biomarker in saliva by HPLC-ECD" by Kawai et al.

Your research team employed the following strategy:

To determine if, and to what extent, Pfizer and Merck are currently involved with "Mouth-as-a-Platform" (MaaP) technologies, our first approach was to conduct an exhaustive search of both companies' press releases since the first of January 2017. Both Pfizer and Merck provide archives of their press releases for the past several years, which allowed us to conduct this review. After reviewing the entirety of both companies' press releases during this time frame, we did not find direct mention of the phrase 'Mouth-as-a-Platform,' nor any evidence of any involvement with technologies resembling the MaaP concept.

As a second approach, we conducted an exhaustive review of the companies' investor relations materials released since the start of 2017. This included Pfizer's 2016, 2017, and 2018 10-K forms; Merck's 2016, 2017, and 2018 10-K forms; and both companies' proxy statements and quarterly reports released within the last three years. Again, we did not find the phrase 'Mouth-as-a-Platform' mentioned in any of these documents, nor did we find evidence of any technologies resembling the MaaP concept.

As a third approach, we searched third-party databases, hoping to find information not published by the companies themselves but nonetheless available in the public domain. One such database was Lens.org, which allows for a granular search of patent applications and filings using a variety of filters. Using this resource, we searched for relevant patents filed by either Pfizer or Merck, using such keywords as 'saliva,' 'salivaomics,' and 'biomarker.' Similarly, we searched for relevant clinical trials conducted by either company using the World Health Organization (WHO)'s International Clinical Trial Registry Platform (ICTRP) as well as Global Clinical Trials Data, using the same keywords. Again, no evidence was found linking either company to relevant technologies.

As a fourth approach, we conducted a generalized press search; while the first approach consisted of searching press releases put forth by the companies themselves, here we sought information published by third-party outlets. Again, we used keywords such as 'saliva,' 'salivaomics,' and 'biomarker' in an attempt to hone in on relevant technologies. Still, we could not find any evidence of either company's involvement with MaaP technology. Given this, we entered 'N/A' in the relevant cells on the attached spreadsheet. Provided above are several potentially useful findings located in the course of our research regarding actions by the two companies related to saliva and biomarkers.
Part
03
of fourteen
Part
03

Competitive Landscape - AmGen & Eli Lilly & Company

After an extensive search of Amgen's and Eli Lilly's press releases and investor relations materials, as well as relevant third-party databases and media sources, no evidence was found linking either company to 'Mouth-as-a-Platform' technologies. As such, we have entered 'N/A' in the relevant cells of the attached spreadsheet. Below are several potentially useful findings regarding these companies' involvement with research and activities related to saliva and biomarkers, followed by a thorough explanation of our research methodology.

Findings

  • Amgen's "Golden Ticket" incubator program assisted Enable Biosciences with development of the company's "Antibody Detection by Agglutination PCR (ADAP) [which] is 1,000 to 10,000 times more sensitive than standard detection techniques," allowing for detection of diseases such as HIV and type 1 diabetes using a small saliva sample rather than more invasive blood samples.
  • A recent study found that this ADAP screening method, using "oral fluid," exhibits "enhanced analytical sensitivity [which] enables this assay to correctly identify HIV-infected individuals otherwise missed by current OF assays."
  • In 2017, Amgen filed a patent related to "the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist." The patent covers samples taken from saliva, among other body fluids.
  • Kelly Oliner of Amgen is acknowledged in a paper regarding the "opportunities and limitations of ctDNA as a clinical biomarker in cancer management," in which tumor DNA found in saliva is discussed.
  • Eli Lilly was a collaborator in an observational study of patients with neurodegeneration and dementia sponsored by McGill University, in which saliva samples were one means of observing patients' health.

Your research team employed the following strategy:

To determine if, and to what extent, Amgen and Eli Lilly are currently involved with "Mouth-as-a-Platform" (MaaP) technologies, our first approach was to conduct an exhaustive search of both companies' press releases since the first of January 2017. Both Amgen and Eli Lilly provide archives of their press releases for the past several years, which allowed us to conduct this review. After reviewing the entirety of both companies' press releases during this time frame, we did not find direct mention of the phrase 'Mouth-as-a-Platform,' nor any evidence of any involvement with technologies resembling the MaaP concept.

As a second approach, we conducted an exhaustive review of the companies' investor relations materials released since the start of 2017. This included Amgen's 2016, 2017, and 2018 10-K forms; Eli Lilly's 2016, 2017, and 2018 10-K forms; and both companies' proxy statements and quarterly reports released within the last three years. Again, we did not find the phrase 'Mouth-as-a-Platform' mentioned in any of these documents, nor did we find evidence of any technologies resembling the MaaP concept.

As a third approach, we searched third-party databases, hoping to find information not published by the companies themselves but nonetheless available in the public domain. One such database was Lens.org, which allows for a granular search of patent applications and filings using a variety of filters. Using this resource, we searched for relevant patents filed by either Amgen or Eli Lilly, using such keywords as 'saliva,' 'salivaomics,' and 'biomarker.' Similarly, we searched for relevant clinical trials conducted by either company using the World Health Organization (WHO)'s International Clinical Trial Registry Platform (ICTRP) as well as Global Clinical Trials Data, using the same keywords. Again, no evidence was found linking either company to relevant technologies.

As a fourth approach, we conducted a generalized press search; while the first approach consisted of searching press releases put forth by the companies themselves, here we sought information published by third-party outlets. Again, we used keywords such as 'saliva,' 'salivaomics,' and 'biomarker' in an attempt to hone in on relevant technologies. Still, we could not find any evidence of either company's involvement with MaaP technology. Given this, we entered 'N/A' in the relevant cells on the attached spreadsheet. Provided above are several potentially useful findings located in the course of our research regarding actions by the two companies related to saliva and biomarkers.
Part
04
of fourteen
Part
04

Competitive Landscape - Novarits and Sanofi

After an extensive search of Novartis's and Sanofi's press releases and investor relations materials, as well as relevant third-party databases and media sources, no evidence was found linking either company to 'Mouth-as-a-Platform' technologies. As such, we have entered 'N/A' in the relevant cells of the attached spreadsheet. Below are several potentially useful findings regarding these companies' involvement with activities and research related to saliva and biomarkers, followed by a thorough explanation of our research methodology.

FINDINGS

  • Novartis is "exploring partnering with Multisensor Diagnostics to develop a proof-of-concept study" for Multisensor Diagnostics's "innovative device to rapidly measure a range of health metrics through breath and saliva."
  • This technology, called MouthLab, seems to closely resemble Mouth-as-a-Platform technology, except that it is not generating continuous insights, but rather rapidly provides insights regarding "respiratory-rate and pattern, pulse-rate, electrocardiogram, SpO2, temperature, blood pressure and lung functions in less than a minute" after users take a breath into it.
  • Novartis collaborated on a study examining the "protective role of Oxcarbazepine in multiple sclerosis" in which saliva tests were one of the testing mechanisms used.
  • Novartis sponsored a study of the pharmacodynamic effects of the drug VAY736 in primary Sjögren's syndrome patients, in which an assessment of B cells in patients' salivary glands was a primary focus.
  • Sanofi sponsored a study "to assess how dengue vaccine efficacy varies across participant subgroups regarding polymorphism in human leukocyte antigen (HLA) alleles of interest." The study's immunogenetic tests were performed on saliva samples.

YOUR RESEARCH TEAM EMPLOYED THE FOLLOWING STRATEGY:

To determine if, and to what extent, Novartis and Sanofi are currently involved with "Mouth-as-a-Platform" (MaaP) technologies, our first approach was to conduct an exhaustive search of both companies' press releases since the first of January 2017. Both Novartis and Sanofi provide archives of their press releases for the past several years, which allowed us to conduct this review. After reviewing the entirety of both companies' press releases during this time frame, we did not find direct mention of the phrase 'Mouth-as-a-Platform,' nor any evidence of any involvement with technologies resembling the MaaP concept.

As a second approach, we conducted an exhaustive review of the companies' investor relations materials released since the start of 2017. This included Novartis's 2016, 2017, and 2018 20-F forms; Sanofi's 2016, 2017, and 2018 20-F forms; and similar reports produced by both companies within the last three years. Again, we did not find the phrase 'Mouth-as-a-Platform' mentioned in any of these documents, nor did we find evidence of any technologies resembling the MaaP concept.

As a third approach, we searched third-party databases, hoping to find information not published by the companies themselves but nonetheless available in the public domain. One such database was Lens.org, which allows for a granular search of patent applications and filings using a variety of filters. Using this resource, we searched for relevant patents filed by either Novartis or Sanofi, using such keywords as 'saliva,' 'salivaomics,' and 'biomarker.' Similarly, we searched for relevant clinical trials conducted by either company using the World Health Organization (WHO)'s International Clinical Trial Registry Platform (ICTRP) as well as Global Clinical Trials Data, using the same keywords. Again, no evidence was found linking either company to relevant technologies.

As a fourth approach, we conducted a generalized press search; while the first approach consisted of searching press releases put forth by the companies themselves, here we sought information published by third-party outlets. Again, we used keywords such as 'saliva,' 'salivaomics,' and 'biomarker' in an attempt to hone in on relevant technologies. Still, we could not find any evidence of either company's involvement with MaaP technology. Given this, we entered 'N/A' in the relevant cells on the attached spreadsheet. Provided above are several additional potentially useful findings located in the course of our research regarding actions by the two companies related to saliva and biomarkers.
Part
05
of fourteen
Part
05

Concept of Mouth-as-a-Platform

The saliva collections and diagnostics market is projected to be valued at $2,630.8 million by the end of 2023. This represents an annual growth rate of 10% over the forecast period of 2018-2022. The largest portion of this is the biotechnology segment, which is projected to be valued at $1,440.6 million by 2022. Following are details on what it is and how it is being used.

Saliva Diagnostics

  • Saliva diagnostics, or salivaomics, utilizes saliva to test and diagnose a variety of conditions and/or markers including stress hormones, cancer, enzyme levels, and disease biomarkers. Based on the provided definition, "MOUTH-AS-A-PLATFORM is defined as capturing vital body functions from saliva and establishing the mouth as a platform for generating continuous health insights," saliva diagnostics is the same as mouth-as-a-platform.
  • Salivaomics, as well as many other types of "omics," developed as a result of the Human Genome Project, which mapped human genes from 1990-2003. The term was coined in 2008 as a result of the rapid progress being made in the study of saliva and its possible impact on overall health.
  • "Currently, there are known five major diagnostic toolboxes of saliva “Salivaomics”: proteomics (the study of proteins), transcriptomics (the study of RNAs), metabolomics (the study of metabolites), microRNA (the study of microRNAs) and microbiome (the study of microbiota)."
  • Using saliva for testing has advantages over using blood because it is easy to collect, does not require needles, and can be done anywhere due the portability of testing kits.

Current Uses

  • A salivary liquid biopsy uses saliva to detect tumor cells in a less invasive way than traditional biopsies. The test can help with early detection, monitoring, identifying targeted treatments, monitoring treatments, and evaluating treatment effectiveness.
  • The National Institute for Health (NIH) funded two studies in 2010 which showed how saliva could be used for detecting oral cancer and Sjogren’s Syndrome.
  • Saliva can be used to detect glucose levels. Although biochemical markers in saliva show up in lower concentrations than in blood, the tests are less invasive and saliva has become a valuable tool for determining if further testing should be done for possible diabetes.
  • Cocaine, marijuana, amphetamines, ecstasy, PCP and opioid drugs can all be detected in saliva and, as a result, employers are using saliva to conduct drug tests on employee. Medical professionals are also using saliva to test for the levels of therapeutic drugs to determine if patients are receiving the optimum dose.
  • DNA testing, by companies such as Ancestry, have become more common and many people have these tests done in order to find more details about their ancestors.

New Technologies

  • In January 2019, ERADA Technology Alliance announced they would be launching a saliva test for malaria. It is expected to increase detection of the disease because of the elimination of needles and the need for blood.
  • Scientists developed a technology that allows for the detection of antibodies in bear saliva. This tech can be used to discover life saving antibiotics for humans.
  • Korean scientists developed a technology which allows for the detection of cholesterol in saliva. The sensor is said to be 1,000 times more accurate than traditional portable sensors that use blood.
  • DNANudge is a UK based startup that will use saliva to determine shoppers DNA and then make food recommendations based on those results.

In Development

  • "A pea-sized biosensor that will measure saliva on your tongue to check glucose levels, and can supposedly be mass-produced in 3D printing at a low cost."
  • A smartphone based saliva test which will allow women to determine if they are ovulating. This would be a cheaper and easier option than the current options of tracking temperatures or conducting a urine test.
  • UCLA received a $5 million grant to develop tools for earlier detection of lung cancer. One of the focuses is on using saliva and blood for liquid biopsies.
  • Based on a breakthrough by scientists in India, tests are in development which will allow for the early diagnosis of both breast and ovarian cancer using saliva. The tests will utilize findings about over 600 proteins that were identified.
  • Research indicates that saliva may be able to be used for the early diagnosis of autism. Researchers found that children with autism have "a set of 32 RNA factors in their saliva could accurately distinguish them from peers without autism." This knowledge can be helpful in developing future non-invasive test.
Part
06
of fourteen
Part
06

Mouth-as-a-Platform Companies 1

23AndMe, Color Genomics, AncestryDNA, Oasis Diagnostics, Diagnos Techs, Salimetrics, Poptest, Perirx, Glucose Biosensor and Chronomics are some companies developing mouth-as-a-platform technologies. Our findings have been presented in the attached spreadsheet rows 2 to 11, columns A to E.

FINDINGS

23ANDME

  • DNA analysis using a saliva sample to get health, ancestry, wellness, and traits analysis done by CLIA certified lab that processes the DNA on genotyping chip to reads genome.
  • Partnership: Alnylam Pharmaceuticals, Inc., Biogen, Genentech, Pfizer, P&G Beauty

COLOR GENOMICS

  • Color using custom software of lab diagnosis to detect cancer risk with 30 genes analyzed including BRCA1 and BRCA2.
  • Partnerships: VISA, Salesforce, Levi's, GE, Wisdom, Jefferson

ANCESTRY DNA

  • Ancestry DNA uses the latest autosomal testing technology to get the family history of each customer that maps ethnicity into multiple generations.
  • Partnerships: National Marrow Donor Program, Calico Life Science, American Society of Human Genetics.

OASIS DIAGNOSTICS

  • This company diagnoses an early disease or medical disorders using a discrete panel to assess hormones and other biomarkers in saliva.
  • Partnerships: Neogen

DIAGNOS TECHS

  • DiagnosTechs uses Coupled Plasma Tandem Mass Spectrometer that performs elemental analysis in saliva specimens in complex matrices with a minimal sample. It also uses liquid and gas chromatography to diagnose the hormones within saliva.
  • Partnerships: Internal Medicine, Mountainview Wellness Centre

SALIMETRICS

POPTEST

  • PopTest pad touch the saliva then read the test result with Smart Phone App, the app will break down the result using colours.
  • Partnerships: Department of Defense, Harvard Medical School, Start, IrsiCaiza

CHRONOMICS

  • Saliva testing kits from the consumer then proceed to their pioneering Next-Generation Sequencing technology to extract DNA result of health condition based on the saliva.
  • Partnerships: Peak Human Labs

GLUCOSE BIOSENSOR

  • After placing the saliva Glucose Biosensor, with the biosensor nearby, using a smartphone, the digital app displays the glucose measurement, and give information with which part needs attention using AI predictive Analysis.
  • Partnerships: iQ Group Global.

PERIRX

  • PeriRx measures early detection of oral squamous cell carcinoma.sugar that is in saliva use proven bio-chemistry technology analytics at high sensitivity.
  • Partnerships: National Cancer Institute, University of Michigan, Michigan State University and the Providence Health System in Detroit.

Part
07
of fourteen
Part
07

Mouth-as-a-Platform Companies 2

Oratel Diagnostics, Mx3 Diagnostics, Helix Dna Test, Narcocheck, Flux Biosciences, Everlywell, Titanovo, Abogen, Firstwatch Health Inc., and Estrogen Gene Test are emerging technology companies in the mouth-as-a-platform space. Details regarding this companies have been provided in the attached spreadsheet.

1. ORATEL DIAGNOSTICS

  • Oratel Diagnostics uses ENDO-TEK, its proprietary and patented technology to diagnose endometriosis. Patients supply a saliva sample and use a mobile app to receive their diagnosis to share with their physician.
  • Currently, Oral Diagnostics has a collaboration with Bayer.

2. MX3 DIAGNOSTICS

  • MX3 Diagnostics conducts hydration testing using an electrochemical test strip for SOSM testing. The company utilizes machine learning, signal processing, and microfluids. The company is innovating further in this space.
  • The company has partnered with many organizations including the Swedish World Cup soccer team, the U.S. military, professional sports teams in the U.S., and multiple NCAA athletic programs.

3. HELIX DNA TEST

  • Helix collects and sequences DNA samples from saliva and provides patient data storage and security. Other DNA-power products can be accessed by patients without the need of providing additional saliva samples.
  • Helix has partnered with Mayo Clinic, Sema4, Renown, Admera health, PerkinElmer, Geising, Genome Medical, and ADX Healthcare.

4. NARCOCHECK

  • Narcocheck designs and manufactures a broad range of quick drug tests usable by professionals and private individuals. The company's THC saliva test (cannabis) consists of only one step, has no saliva manipulation, and delivers results in 10 minutes. The Cannabis saliva kit can test 5 other drugs including THC, COC, OPI, AMP, and MDMA.
  • Narcocheck’s partners are primarily their distributors of medical, pharmaceutical and para-pharmaceutical equipment.

5. FLUX BIOSCIENCES

  • Flux Biosciences uses saliva to measure biomarkers related to exercise, stress, fertility, and diet. It also correlates those measurements to sleep and activity data gathered using wearable technologies. Flux Biosciences also uses urine and blood for various tests.
  • The company partners with Stanford.

6. EVERLYWELL

  • Everlywell performs various diagnostics tests. The company offers an interesting at-home testosterone test kit for men.
  • In this case, a test kit is delivered to the user’s doorstep. The user then completes a simple saliva sample collection. The kit is then mailed to Everlywell, and once analyzed, the results are sent to the user via a secure platform.
  • Everlywell has a partnership with Helix DNA Test.

7. TITANOVO

  • Titanovo has a direct-to-consumer, saliva-based Telomere Testing Kit that can be purchased online. The kits can conduct wellness testing based on genetics and use other biomarkers to generate results.
  • The company has a partnership with Startup Health.

8. ABOGEN

  • AboGen is a commercial-stage medical device startup providing transformative technology via a saliva-based collection and preservation technology created to preserve all the components found in saliva. The company aims to replace the over 5 billion blood tests performed yearly.
  • Abogen partners with Maineangels.

9. FIRSTWATCH HEALTH INC.

  • Firstwatch Health Inc. is among the first saliva-based and self-testing platforms that is enabling better health and wellbeing. The platform delivers instantaneous results, starting with prediabetes, stress, and cardiovascular checks.
  • Firstwatch Health Inc. partners with fitness companies.

10. ESTROGEN GENE TEST

  • Estrogen Gene Test is a saliva-based genetic testing company that utilizes 11 estrogen metabolism genes, which provide a gene by gene action plan to improve estrogen health. EstroGene is available directly to consumers and their physicians and customers can choose to receive their test results from EGT healthcare practitioners.
  • EstroGene has a partnership with General Genetics Corporation.

RESEARCH STRATEGY

To identify 10 emerging technology companies in the mouth-as-a-platform space, we started by searching through various medical and biotech reports that focus on genomics, genes, and saliva technology. We examined multiple reports including those published by Frontline Genomics and Startup Health, business sites such as Bloomberg, and startup technology platforms like Techcrunch and Crunchbase. These sources provided several examples of emerging technologies in the saliva-based testing space. For each company we found, we further searched through its website and other business profiling sites to retrieve in-depth information. Crunchbase, which profiles startups including details about their products, services, and funding information featured several examples of companies matching the requirements, particularly in the biotech space. The details of these companies are included in the attached spreadsheet rows 12-21, columns B-E.
Part
08
of fourteen
Part
08

Mouth-as-a-Platform Companies 3

Ten emerging companies in the mouth-as-a-platform space include OraSure Technologies, Inc., StatSure Diagnostic Systems, Salignostics, Securetec Detektions-Systeme AG, MAVAND Solutions GmbH, OralDNA Labs, Quest Diagnostics, Prenetics, NEPeSMO, and Xcode. We have provided this information in the attached spreadsheet.

#1: ORASURE TECHNOLOGIES, INC.

  • OraSure Technology has two family of products and test kits that are based on saliva. They are the Oragene family such as the Oragene.Dx and the Q.E.D Alcohol Test. The Oragene family are non-invasive self-collection kits that are used and able to stabilize saliva DNA samples in preparation of other diagnostic tests. The Oragene.Dx has been cleared by the FDA. The Q.E.D Alcohol Test is a "CLIA-waived and U.S. DOT-approved, rapid, low-cost alternative to alcohol breath or blood testing."
  • Partnerships include various diagnostics and pharmaceutical companies such as Schering-Plough Corporation.

#2: STATSURE DIAGNOSTIC SYSTEMS

  • StatSure develops and designs the Saliva Sampler, a fluid collection device. The product provides non-invasive access to body fluids like saliva as specimens for the purpose of drug testing.
  • The company is in partnership with Clinivation Enterprise Solution.

#3: SALIGNOSTICS

  • Salignostics offers solutions that utilize saliva as a diagnostic body-fluid. Its kits such as the PregKit "prepares saliva as an optimal and reliable diagnostic sample" for a variety of rapid diagnostic tests such as pregnancy, ovulation, H.Pylori and malaria.

#4: SECURETEC DETEKTIONS-SYSTEME AG

  • Securetec develops the DrugWipe® S test device that is able to detect drug in the saliva within five minutes. The target drugs include cannabis, opiates, cocaine, amphetamines, methamphetamines (MDMA, ecstasy), benzodiazepines and ketamine.
  • Suretec has partnerships with various companies in the science and industry space, as well as sales and marketing brands.

#5: MAVAND SOLUTIONS GMBH

  • MAVAND develops Rapid STAT®, a revolutionary point of collection test that are conducted on body fluids such as saliva to detect drugs of abuse like marijuana and cocaine. It is fast and convenient.
  • MAVAND partners with several universities and authorities including police forces.

#6: ORALDNA LABS

  • Through its salivary diagnostics, "OralDNA helps healthcare providers treat, heal, and inspire oral health." These tests include MyPerioPath for periodontal diseases and OralRisk HPV for HPV-related oral cancer.
  • OralDNA has a partnership with the Wellness Dentistry Network.

#7: QUEST DIAGNOSTICS

#8: PRENETICS

  • Prenetics develops saliva-based tests for genetic purposes including pharmacogenomics and nutrigenomics. Nutrigenomics concerns how the food humans eat impact on their genes while pharmacogenomics focuses on the impact of the drugs on the genes.
  • Prenetics partners with various insurers and fitness brands such as DNAFit and HSBC Insurance.

#9: NEPESMO

  • NEPeSMO focuses on saliva-based tests that geared towards the prediction of possible lung diseases, as means of prevention. "It uses proprietary prediction algorithms are constructed from time-series data on symptoms, lung function and biomarkers in blood/saliva supplied by patients using a bespoke App that connects wirelessly to monitoring devices."
  • NEPeSMO partners with patients, clinicians, hospitals, policy-makers and the Industry.

#10: XCODE LIFE

  • Xcode Life collects saliva samples and conducts tests on them for the identification and prevention of "genetic predispositions for certain diseases (such as diabetes) into serious disorders."
  • Xcode has a partnership with Lark Health.
Part
09
of fourteen
Part
09

Mouth-as-a-Platform Competitive Landscape 1

On the attached spreadsheet, rows 3-9, we have compiled information on companies in the mouth-as-a-platform vertical, including Pop Test LLC., PeriRx LLC., Helix DNA Test, Narcocheck, and Flux Biosciences.

1. POP TEST LLC

Overview

  • Pop Test performs saliva diagnostics tests for diabetes, NASH/Fatty liver disease, uric acid for gout, and cholesterol. It uses proprietary technology where users touch saliva to a test pad and then read the test pad using a smartphone application, which breaks down each color by digital results.

History

  • According to Hoovers, Pop Test LLC was incorporated in 2014. It is based in Cliffside Park, NJ.
  • Pop Test LLC’s first saliva diagnostics proprietary technology patent was filed in July 2008 and approved in November 2010.
  • In 2018, Pop Test signed a letter of intent with QualHealth seeking to commercialize the key technology. It is anticipated that QualHealth will launch the Pop Test Saliva Diabetes Screening tests in 2019.

Products

  • While there are several products in the pipeline, presently, the Pop Test Pad is the company’s primary product. [source 1]

Funding

  • There was no information on funding.

Claims

  • The letter of intent Pop Test LLC signed with QualHealth in 2018 will significantly increase the number of diabetes screenings performed in the U.S. and around the world to improve early detection of diabetes.

Team

  • Randi Altschul, CEO
  • John Gregg, MBA, COO
  • Robert Foerster, MBA, CFO, Business Development
  • Neil Theise, MD, Lead Scientist
  • Razvan Ene, PhD, Director, Worldwide Operations

2. PERIRX LLC.

Overview

  • PeriRX develops non-invasive, oral diagnostic technology that uses proven bio-chemistry analytics at high sensitivity and specificity to enable early disease risk detection. SaliMark™ OSCC is the company's first commercial saliva test for the early detection of oral squamous cell carcinoma.

History

  • PeriRX Llc was founded in 2008 by Stephen M. Swanick and is based in Broomall, Pennsylvania. It was established to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection.

Products

Funding

Claims

  • PeriRx claims that SaliMark™ OSCC has been clinically-validated in multiple large trials including various collaboration studies with the National Cancer Institute, University of Michigan, Michigan State University, and the Providence Health System in Detroit.

Team

Stephen M. Swanick — President, CEO and Founder
Dr. Neil Gottehrer — Dentist
Dr. Jack Martin — Cardiologist

3. HELIX DNA TEST

Overview

  • Helix is a health company that focuses on personal genomics and provides people with insights into their own DNA.
  • The company is dedicated to making DNA learning accessible and useful for everyone. Helix seeks to unlock more genetic data to allow individuals to make informed decisions regarding their health, fitness, nutrition, and more.

History

  • Helix was founded in 2015 by James Lu, Justin Kao, and Scott Burke. It is headquartered in San Francisco. It focuses on big data, biotechnology, genetics, healthcare, personal health, and wellness. In 2018, helix acquired HumanCode, which creates futuristic personal genomics applications.
  • During the same year, Helix expanded its senior leadership team with the introduction of Ajay Gopal as CFO, Deena Bahri as the CMO, and Chris Glode as the CPO.

Products

Funding

  • $300 million
  • Investors: Temasek, Sutter Hill ventures, DFJ, KPCB, illumine, Warburg Pincus, and Mayo Clinic.

Claims

  • Helix claims to offer unique and innovative products designed to meet the needs of all users. Their clinical-grade genomics platform provides flexibility, delivering accurate and actionable insights. The company relies on unrivaled in-house expertise, uses proprietary CLIA/CAP Exome+™ sequencing technologies, and they only sequence and securely store a whole exome.

Team

Marc Stapley
Chief Executive Officer
James Lu, MD, PhD
Co-founder & SVP, Applied Genomics
Justin Kao — Co-founder & SVP
Chris Glode — Chief Product Officer
Ajay Gopal — Chief Financial Officer
Dawn Barsy — VP, Legal
Jade Curtis — VP, People Operations
Jim Chou — VP, Engineering
Will Lee, PhD — VP, Bioinformatics
David Becker, PhD — VP, Laboratory Operations
Marc Laurent — VP, Operations
Roberto Veronese — VP, Product Design

4. NARCOCHECK

Overview

  • NarcoCheck offers a complete range of rapid drug tests for the detection of narcotics and drugs of abuse. It designs and builds high quality drug screening devices for medical customers and multiple companies globally to manage and prevent drug abuse related risks.

History

  • NarcoCheck was founded in 2005 to design and manufactures a comprehensive range of rapid drug tests for use by professionals and private individuals. Based in Montluçon, France, NarcoCheck does not have a sales team, instead, it partners with healthcare professionals or medical centers to sell its products globally.

Products

Funding

  • There was no funding information indicated on website or external sources.

Claims

  • NarcoCheck claims to be focusing on providing its customers with high quality products approved by the FDA and CE. They conduct quality controls throughout the manufacturing chain.
  • NarcoCheck also claims to hold very competitive prices compared to their competition. For instance, their prices reflect the current prevailing costs of raw materials, which are affected by seasons, suppliers, and availability.

Team

  • There is no mention of the company’s staff on their website and external sources. This is so because it works under Kappa City Biotech.

5. FLUX BIOSCIENCES

Overview

History

  • Flux Biosciences was founded in 2017 by Tyler Schultz and Shan X. Wang. It is based in Palo Alto, California.
  • The company has not been acquired or made any acquisitions. Moreover, there has not been any changes in the senior leadership. Flux Biosciences won $500,000 in the 2017 Change The World Competition by Forbes.

Products

Funding

Claims

  • Flux Biosciences claims that, previously, their technology used to read and write computer hard drives. However, they repurposed it to start performing sensitive and quantitative point-of-care in vitro medical diagnostics. The technology measures biomarkers related to exercise, stress, fertility, and diet by relying on saliva, urine, or blood.

Team

Tyler Schultz — Co Founder & CEO
Shan X. Wang — Co Founder
Travis McCain — Chief Product Officer

Research Strategy:

To find the information requested on the attached spreadsheet for each company, we started off by exploring each company’s website to retrieve information on the leadership, company overview, products, claims, and history. Luckily, we uncovered in-depth information for each of the identified companies. For funding information, we uncovered the details for Helix and Flux Biosciences on Crunchbase and those for PeriRx were reported on its website. In this regard, funding information for Pop Test LLC and NarcoCheck were neither reported on their respective websites nor on Crunchbase, which features funding details for many startups, as they were not profiled on Crunchbase. For NarcoCheck, we assumed that since it works under Kappa City Biotech, it is unlikely that it reports or discloses such information since it is privately held. Attempts to scour through Kappa City Biotech's website also proved futile as there was no information on NarcoCheck funding. For Pop Test LLC, similar approaches were used to find its funding. Being a privately held company, we concluded that it is highly probable that it does not reveal its financial information to the public.
NarcoCheck did not feature any information on their team on their site. Equally, it does not have a business profile on LinkedIn. Therefore, we could not provide an estimate of their head count. We suspect that the lack of that critical information is because the company is part of Kappa City Biotech. On LinkedIn, Kappa City Biotech only featured brief mentions of NarcoCheck with no in-depth information regarding its leadership. The mentions focused on NarcoCheck’s capabilities but not its staff. Also, since NarcoCheck relies on external people as its partners to sell and distribute their products, it is likely that they lack an expansive internal team.

Part
10
of fourteen
Part
10

Mouth-as-a-Platform Competitive Landscape 2

All requested information have been provided in the spreadsheet.

OVERVIEW OF FINDINGS

EVERLYWELL

Company Overview

  • EverlyWell offers access to laboratory testing for wellness monitoring, informational and educational use.
  • With the exception of certain diagnostic test panels, the test they offer access to are not intended to diagnose or treat disease. None of the company's tests are intended to be a substitute for seeking professional medical advice, help, diagnosis, or treatment.

Products

  • Everylwell provides diagnostic health testing services.
  • The company offers testing services in Food sensitivity, thyroid test, Vitamin D test, Metabolism test.

C-SUITE EXECUTIVES

Fundings

  • The company has received a total of $55,000,000 in fundings.

SALIGNOSTICS

Company Overview

  • Salignostics is an R&D company focusing on the development of saliva based rapid diagnostics tests (RDT).
  • The company's platform is comprised of a "tool box"​ of technologies which amplify the saliva as a detectable body-fluid by overcoming different chemical and biological saliva related obstacles. Implementation of these technologies transforms saliva from a non-detectable to a detectable body-fluid.

Products

  • The company product is PregKit which is the first and only saliva based pregnancy test.

Leadership Team

  • Guy Krief (PhD) - Co-Founder, Deputy CEO and CBDO.

Funding

N/A

PRENETICS

Company Overview

  • Prenetics is the leading genetic testing/digital health company in Southeast Asia.
  • The company seeks to empower patients and clients with valuable health information. Using the patients saliva sample, they can discover how their genes affect their diet, drug response, disease and cancer risk.This information enables people to make health a choice, by living healthier and proactively preventing diseases.

Products

  • In 2018, the company announced the launch of Circle, a consumer DNA testing platform. The initial offerings include Circle's Cancer DNA test and Diet Fitness Pro 360 test.

Leadship Team

  • DANNY YEUNG - Chief Executive Officer - Prenetics Group. (S 9)
  • AVI LASAROW - Chief Executive Officer – Prenetics International. (S 9)

Funding

  • The company has received a total of $52,700,000 in funding.
  • Additional information can be found in the attached spreadsheet.

COnclusion

  • Salignostics company product is PregKit which is the first and only saliva based pregnancy test.
  • Everlywell has received a total of $55,000,000 in fundings.
  • Prenetics is the leading genetic testing/digital health company in Southeast Asia.

Research Strategy:

We began our research by leveraging information from company website, news and media publications, and company profiling sites. From these sources, we were able to find actionable data that guided us to provide most of the requested information. However, we could not get any detailed information on Firstwatch Health. We started our search by looking for information on the company profile. We found out that the site is down and not currently accessible. All effort to access the site for information was unsuccessful. Next, we tried looking for the company profile on company profiling databases such as Crunchbase, Hoovers, Bloomberg, and Linkedln. We found out that the company has no information or profile on any of the databases apart from Crunchbase. The information we found there we also limited and not detailed. We have, however, provided the little information we found in our report.



Part
11
of fourteen
Part
11

PARC Overview

PARC, owned by Xerox, can be accredited for many of today's technological advances. They have created $1 trillion in new industries and have almost 6,000 patents and applications. Their mission is to create the "Open Innovation Center of the 21st Century".

BACKGROUND INFORMATION

  • PARC provides "custom R&D services, technology, expertise, best practice and intellectual property to a whole range of companies, from Fortune 500 and Global 1000 firms to startups and government agencies all over the world".
  • They are located in Silicon Valley, and operate globally.
  • PARC has created $1 trillion in new industries, $60 billion in startups, and has almost 6,000 patents and patent applications.

HISTORY

  • PARC, established in 1970, has been key to many of the "most important technological breakthroughs of our time".

PARC Historic Timeline

  • 1970- Xerox PARC founded. Their group of scientist become known as the "Architects of Information". They establish the Xerox Palo Alto Research Center.
  • 1971- Creates a bit-mapped laser for printing
  • 1972- Smalltalk is designed and object oriented programming revolutionizes the software industry.
  • 1973- The Alto PC personal workstation is created with a client server architecture.
  • 1973- An internal memo from a scientist proposes to link workstations, files, and printers together. Ethernet is born.
  • 1973- Superpaint records the first video image.
  • 1974- WYSIWYG- PARC coins this phrase to describe cut-and-paste editing. (What You See Is What You Get)
  • 1974- Bravo word processing is introduced. This will later become Microsoft Word.
  • 1975- GUI (graphical user interface) is debuted.
  • 1977- Very Large Scale circuit design is introduced.
  • 1979- Natural Language Processing is introduced and enables spell checking.
  • 1980- Optical storage that is non-erasable technology is developed.
  • 1982- The first fiber optic cable becomes operational.
  • 1983- a-Si for printing is developed. It is a silicon, thin film transistor.
  • 1986- Multi-beam lasers that print twice as fast are developed.
  • 1987- PARC designs UNICODE, a multilingual coding system.
  • 1988- They coin the term Ubiquitous computing.
  • 1989- Embedded data glyphs are developed.
  • 1990- Cognitive capacities are incorporated to visualize large amounts of information.
  • 1990- Multi-user virtual worlds are created.
  • 1992- Collaborative filtering is implemented.
  • 1997- Blue lasers are introduced.
  • 2000- Electronic usable paper is developed.
  • 2001- Biomedical systems are developed to accelerate discoveries in life sciences.
  • 2007- Powerseat language search company partners with PARC and develop breakthrough technology in consumer searches.
  • 2010- PARC partners with PowerCloud to offer cloud managed networking solutions.
  • 2017- PARC partners with Metawave to build AI technology solutions.

COMPANY CULTURE

  • PARC is the champion of the "entrepreneurial scientist". A scientist that is an innovator that is passionate about "deep research".
  • They pride themselves on a collaborative and accepting workplace.
  • They encourage their employees to volunteer, even giving them paid time off.
  • Their mission is to create the "Open Innovation Center of the 21st Century".

CLEAN ROOM SERVICES

  • One of their key assets is their Clean Room Services. These facilities allow client to develop prototypes quickly and cost-effectively.
  • This process can rapidly take projects from concept to production, while working with next generation materials.
  • Optoelectronic devices can be fabricated.

FOCUS AREAS

  • PARC focuses their work around Focus Areas that they believe are the future of technology. These focus areas are led by experts in their fields.

AI & Human Machine Collaboration

Digital Workplace

  • This focus are deals with artificial intelligence and the Internet of Things. They work with clients to improve "physical and digital worlds".
  • "Intelligent assistants, augmented reality, sensors, and analytics-driven services that enable responsive and reconfigurable spaces" are all areas of focus.

Novel Printing

  • This focus area covers "on-demand printing, industrial printing, flexible electronics and additive manufacturing".

IoT & Machine intelligence

  • The goal of this are is to move towards an IoT empowered world.
  • "At PARC, we’re working with clients and partners to develop the technologies that can enable this mass transition. With analytics front of mind, our labs are creating smart sensors and systems that enable rapid, reliable and secure data collection at scale. This data can then be used to develop actionable insights, or as the backbone of systems that will be at the forefront of a rapidly changing technology landscape."

Digital Design Manufacturing

  • By working with new algorithms, they are creating new ways to analyze and plan the manufacturing of complex structures.
  • "Our interdisciplinary work unifies principles of computational physics, geometric reasoning, automated spatial planning, and field modeling to help engineers create entirely new kinds of products — the likes of which many have not yet imagined."

Microsystems & Smart Devices

  • By working with hardware systems like "sensors, actuators, displays and cameras, they are reinventing them to be more accessible.
  • They use smart analytics to improve upon these technologies.

COMPETENCIES

  • PARC uses Competencies (disciplines). When a new project is encountered, they bring in people from all of their competencies to make sure they stay on the cutting edge.
  • Their Competencies consist of: AI & Human-Machine Collaboration, IoT & Machine Intelligence, Digital Design & Manufacturing, Microsystems & Smart Devices, Novel Printing, Digital Workplace.
  • More information on each Competency can be found here.

RECENT ACCOMPLISHMENTS/PRESS RELEASES

Using IoT and AI To Improve Rain Maintenance

  • PARC used MOXI technology to improve Japan's railways.
  • MOXI utilizes model based algorithms that "enabled 90% higher accuracy and low false alarm rates". This enabled them to run on time more often.

Energy Storage & Air Quality-

  • PARC secured two CalSEED awards to improve energy storage and air quality.
  • With these awards they will develop a desalination battery and a membrane-based Electrochemical CO2 Removal System.

Space R&D

  • PARC is partnering with Blue Origin to enhance awareness and interest of conducting R&D in space.
  • They will focus on "advanced manufacturing, energy systems, human-machine interaction, and predictive analytics."

Inkless Photonic Printing Solutions

  • PARC is partnering with Datalase to develop laser based hardware solutions, including color-changing pigment technologies.

Improving Grid Reliability

  • The US Department of Energy awarded PARC a grant to develop TRANSENSOR, a monitoring system. It will provide real time asset health readouts.

Ultra Thin Audio Speakers

  • PARC has partnered with FlexTech to develop a paper like smart tag that has a thin audio speaker.
  • This product is geared for applications in packaging, prosthetics, robotics, and smart cities and homes.

Health Care Solutions

  • PARC has partnered with Innovation Labs to take on health care issues by using medical technology, engineering, and robotics.

DARPA (Defense Advanced Research Projects Agency)- Explainable Artificial Intelligence

  • PARC has been selected by DARPA to develop a highly interactive "sense making system called COGLE (Common Ground Learning and Explanation), which may explain the learned performance capabilities of autonomous systems to human users."
  • "The key idea behind COGLE is to establish common ground between concepts and abstractions used by humans and the capabilities learned by a machine. These learned representations would then be exposed to the human via COGLE’s rich sense-making interface, enabling people to understand and predict the behavior of an autonomous system."

Modeling ToolS For Manufacturing

  • "DARPA Chooses PARC, Siemens, Georgia Institute of Technology, and Michigan State University to Develop Modeling Tools to Transform State-of-the-Art Manufacturing"
  • The goal of this technology is to expand computer aided design.
  • “This project will have significant impact for high-performance products in specialized industries such as aerospace, defense, automotive, energy production, manufacturing tooling, medical devices and consumer products,” said Dr. Suraj Musuvathy, Senior Scientist, Siemens Corporate Technology"

AI Research

  • "PARC, a Xerox company, today announced it has been selected, alongside University at Buffalo, for a DARPA project to develop novel hybrid methods that combine multi-physics, equation-based models with data-driven machine learning models [such as Deep Neural Networks (DNNs)] to enable predictive modeling of complex systems in the presence of imperfect models and sparse and noisy data."
  • “We’re teaching physics to AI systems,” said the grant’s principal investigator Rahul Rai, PhD, associate professor of mechanical and aerospace engineering in UB’s School of Engineering and Applied Sciences. “We are developing hybrid methods that integrate physics-based models — these are math-based formulas that explain the world around us, such as Einstein’s E=MC2 — into the algorithms that guide machine learning, deep learning and other data-driven AI systems,”

Configuration Security Project

  • "The Palo Alto Research Center, Inc. (PARC, a Xerox company) and George Mason University (GMU) have been awarded a contract from the Defense Advanced Research Project Agency (DARPA) Configuration Security program (ConSec). Within ConSec, researchers from PARC and GMU will collaborate on a project christened SCIBORG: Secure Configurations for the Internet of Things (IoT) based on Optimization and Reasoning on Graphs. The goal of SCIBORG is to devise fundamentally new approaches to determine security configurations that protect critical infrastructure and IoT-based systems.
  • "SCIBORG will measure its success in terms of the reduction of the impact of potential attacks".

Low Cost CO2 Sensors

  • The US Department of Energy selected PARC to develop- low cost CO2 sensors.
  • These sensors heat up when they detect CO2.

Partnership to Develop Advanced Mechanical Systems

  • PARC has a "partnership with University of Wisconsin-Madison, by DARPA, for a project in the Engineering Fundamental Design (FUN DESIGN) program. DARPA, whose mission is to identify and pursue high-risk, high-payoff research initiatives for national security across a broad spectrum of science and engineering disciplines, announced the first programs under its new Disruptioneering effort".

CURRENT BREAKTRHOUGH TECHNOLOGIES

Wavelength Shift Detector

  • This detector, developed by PARC, can monitor light sources at extremely high resolution and is a low cost unit.

Fittle

  • Fittle focuses on behavior changes to improve health. It employs mobile sensing.
  • It is a smartphone app that incorporates group support, rewards, tracking and logging.

Hyperspectral Imaging Technology

  • "PARC is actively working to enable the hyperspectral imaging ecosystem with PARC’s hyperspectral imaging technology, which is the only such technology with the size, weight, cost and performance suitable for mass-market adoption. Based on an elegant reversal of the operating principle of a liquid-crystal display, the PARC technology relies on a liquid-crystal layer about as thick as a human hair to encode hyperspectral information. It can therefore be integrated anywhere image sensors are currently used, including on smartphones."

Hipergraph

  • Hipergraph is an algorithm to analyze complex data sets.

Hand-Held Flow Cytometer

  • This cytometer is used in research settings to examine biological cells.

Filament Extension Atomizer

  • This innovation tackles the problems of difficult to spray materials.
  • Its applications include consumer application, medical, spray coating, and food processing.

Makesim

  • Makesim introduces novel "geometric reasoning techniques" to improve 3D printing.

Self-Cooling Paint

  • This paint can cool any surface up to 10 degrees.

Fiber Optic Sensing Systems

  • These sensing systems are for asset monitoring. They are more cost effective.

FIELDS

  • This is a new approach for computer aided design.

Dialog Systems

  • This technology explores virtual assistants, call centers, and other applications for interactive dialog.

Printed Gas Sensing

  • This is a low cost technology to monitor a wide variety of gasses.

CoExtrusion

IIoT System Analytics

  • MOXI IIoT Analytics use AI to predict at 90% accuracy.

Ultraviolet and Visible Semiconductor Lasers

  • "High Performance Optoelectronic Laser Device Technology-Since the invention of the laser in 1958, these sophisticated devices have continued to revolutionize our lives. In the process, they have contributed to the generation of an enormous list of new applications in the fields of telecommunications, data storage, consumer electronics, spectroscopy, materials processing, bio-photonics, and life sciences. "

Micro Assembler Printer

  • Digital processing is used to rapidly assemble micro objects.

Research Strategy

Please note that quotation marks were used to not alter the scientific jargon.


Part
12
of fourteen
Part
12

Research Topics 1

In the past few years, the signal-to-noise ratio needed to successfully detect changes in biometrics via saliva analysis has greatly reduced. In fact, we can now detect biochemical markers at such low levels that there is now a question about when the thresholds of various biomarkers becomes significant.

SIGNAL-TO-NOISE TOLERANCES ARE GROWING


SNL RATIOS ARE BEING USED TO IDENTIFY BIOMARKERS

  • Other techniques, in part, use the SNR to determine content within a saliva sample. For example, in a technique to detect the N-glycosylation of immunoglobulin, "Whether an analyte was present in a sample, was determined based on the signal-to-noise ratio (S/N; > 9), the isotopic pattern quality score (IPQ; < 0.2) and the mass accuracy (<10 ppm deviation) of each signal per charge state."

THERE ARE TRADE-OFFS TO GETTING BETTER SNR

  • As noted by one biochemical expert, "On the one hand scanners with higher field strength inherently have greater signal-to-noise ratio which should improve measurement reliability. On the other hand, echo planar images from higher strength scanners are also more affected by dropout caused by the susceptibility artifact," which is a concern for certain types of testing.

LOWER SNR THRESHOLDS RAISE QUESTIONS OF SIGNIFICANCE

  • Questions remain about how to interpret the data; namely, with the ability to detect biomarkers at such low levels, do they lose their significance?
  • "If a biomarker is detected at all, does that mean disease is present or will develop—or is biomarker presence below a certain level considered 'normal' for baseline?"

RESEARCH STRATEGY

In undertaking this project, we faced two primary obstacles. First, while the abstracts of nearly every scientific paper are available online, the body of the research, which would contain more information on the "signal-to-noise" ratios inherent in detecting biomarkers in saliva, is often available only at cost. Second, where the full articles are available, they are written for specialists in this field, not the layman, and while we could follow the general gist of the research, we were not confident in our ability to properly "translate" them. (For this reason, our findings above are unusually heavy in direct quotes, lest we unintentionally introduce errors while trying to paraphrase scientific works.)

Therefore, we began by searching for articles written in mainline science or other news sources for the general public, trusting that we would be able to trace the information contained therein back to the original academic work. While we found some general interest articles on using saliva as a new diagnostic technique that provided some background, they did not directly address — or even mention — the issue of how the SNR factored into various techniques with only a few prominent exceptions.

Equipped with the background, we returned to the scientific papers, which we searched using Google's Scholar database. This enabled us to see which papers were citing which other papers, enabling us to quickly scan for updates to each research paper.

Note that while we often forego our standard criterion of restricting ourselves to sources published in the last two years when dealing with academic works (due to the long research and publication cycles involved), in this case we found that SNR detectability is growing so rapidly that it was advisable to use only the most recent available studies.
Part
13
of fourteen
Part
13

Research Topics 2

While both scientific studies and home-testing kits routinely have the subject fast, rinse their mouths, or both before taking the sample, an extensive search of available public documents does not reveal any studies which attempt to correlate contamination with degregation of the signal-to-noise ratio (SNR). We hypothesize that studies are careful to remove possible contaminants such as food as a matter of removing possible variables from the test. In the case of the home-test market, the range of decontamination procedures — from fasting and rinsing to none at all — may indicate that the risk of false readings from contaminants depends on the nature of the test, though this is just a hypothesis.

Below is an overview of our findings and a detailed research strategy to explain why a direct answer is not possible from the available data.

CONTAMINATION CONCERNS IN SALIVA TESTING

  • The Raman spectography technique lists among its advantages that it "has low water interference, high signal-to-noise ratio, and high sensitivity compared with Fourier infrared spectroscopy."
  • Even so, clinical trials, which admittedly involved freezing saliva samples for later use, required 12 hours of fasting overnight, followed by the subjects washing their mouths with water three times before the sample was taken.
  • Even then, the collected saliva "was centrifuged at 13,900 rpm for 10 min to remove oral epithelial cells and any residual food debris."
  • Likewise, an online book entitled "Salivary Diagnostics" warns against blood, food products, and sodium azide as possible contaminants of saliva samples.
  • When taking whole saliva samples, the patient is advised to avoid eating, drinking, brushing their teeth, or using mouthwash for an hour before the sample is taken.
  • When taking a submandibular or sublingual sample, the subject is told to rinse with distilled water for a full minute before the sample is taken.
  • However, when taking samples directly from the salivary duct or collecting parotid secretions, a sterile tube can be used to take saliva directly from the duct. While this does not require cleaning the site, the process takes 15-20 minutes to obtain a complete sample.

CONTAMINATION IN HOME TESTING KITS

  • Another article on saliva collection which refers to home testing notes that in addition to having the subject rinse with water, they may also "chew an inert material such as a piece of rubber or paraffin wax from 30 seconds to several minutes," presumably to remove food and other foreign particles.
  • The need to remove contaminants may depend on the type of test. For example, InnerHealth's FAQ, answering how to take a sample, advises neither eating nor drinking for 15 minutes before taking the sample, while a home HIV test kit makes no mention of cleaning the mouth before taking a swab. Neither source explains the rationale behind their procedures.
  • Walk-In Lab, on the other hand, is ambiguous, stating that a client "may" discard a sample in which they forgot to wash out their mouth first, but also indicating that they could still send it in. We hypothesize that Walk-In Lab may take steps to remove contaminants in samples (as in the previous section) after they arrive.

DEVICE-BASED SALIVA TESTING AND CONTAMINATION

  • In a 2015 paper entitled "Noninvasive glucose monitoring using saliva nano-biosensor," care was taken to rinse the mouth before beginning the test. Though some possible contaminants were detected on the biosensor, they did not appear to unduly influence the results.

RESEARCH STRATEGY

We began our research by studying articles on how saliva samples are typically taken for analysis in order to find out whether contamination by food, water, or other substances is typically a concern. This quickly led us to two scientific papers which described one or more collection methods in detail. These demonstrated that it is typical to wash the mouth beforehand, and even to have the patient fast for an hour or more, indicating that cross-contamination is indeed of concern and that doctors taking samples take reasonable steps to avoid it. However, both of these were in the context of taking samples in a clinic with the intent to process and store them.

This left open the question whether a home testing kit, or even a continuous monitoring device in the mouth, would be equally concerned about contamination. (Perhaps the concern is whether contaminants would carry bacteria that would grow over time and ruin the sample?) We, therefore, studied existing home kits to see if their instructions emphasized the need to cleanse the mouth first. This strategy gave inconclusive results, as detailed in our findings above.

Finally, we searched for papers detailing the testing of devices or kits intended for home use, both to determine whether we continued to see a pattern of cleansing the mouth before testing and to discover whether any had attempted to determine the loss of the SNR as a result of testing without decontamination first.

Note that where academic papers are available, they are written for specialists in this field, not the layman, and while we could follow the general gist of the research, we were not always confident in our ability to properly "translate" them. For this reason, our findings above are unusually heavy in direct quotes, lest we unintentionally introduce errors while trying to paraphrase scientific works.
Part
14
of fourteen
Part
14

Research Topics 3

While there have been many advances in wearable biosensors in the last few years, there appears to be a very limited range for those designed around the human mouth. Indeed, apart from one experiment in nano-biosensors, most of the effort appears to have centered on creating biosensor mouthguards. Of the several proofs-of-concept which follow that form, only one has been taken to market, unsurprisingly designed for the athletic community.

BIOSENSOR MOUTHGUARDS

  • As noted in a 2018 paper on wearable sensors, "the key component for salivaomics, wearable sensors are usually constructed in a mouthguard to promote their wearability."
  • While the papers and abstracts referenced in the above paper do not deal extensively with comfort, the proliferation of mouthguard biosensors in both papers and mainline news and education sources, along with the relative absence of alternatives (but see below), suggests that this is the primary and most comfortable method to enable a patient to wear a saliva-monitoring bio-sensor.
  • However, while bio-sensor mouthguards have been in development since 2015, the only mouthguard-mounted sensor that seems to have reached the market (to wide acclaim) is the Prevent Biometrics mouthguard, which is being marketed as a tool to help detect and prevent further repetitive head trauma for athletes. See below for speculation on why.

NANO-BIOSENSORS

  • In 2016, Dr. Wenjun Zhang developed a disposable nano-biosensor which could be placed in the mouth and detect blood glucose level. However, this sensor seems to have remained at the proof-of-concept phase (it does not appear to be marketed) and while the test claims that this method allows "collecting biological samples with minimal discomfort," it does not provide any data about the comfort of the patient.

FORM FACTOR AND COMFORT

  • Features key to comfortable long-term wearing of a bio-sensing device include "bio-compatibility, compactness with skin, durability, size and weight."
  • Avoiding obtrusiveness is another key to making sure a person will wear their biosensing device. "To make health care unobtrusive, it’s important to take health-monitoring advancements a step further than externally worn smart medical devices."
  • We hypothesize that this is why the only mouthguard sensor that has taken hold on the market is designed with athletes in mind. That is, to an athlete, a mouthguard is a familiar, unobtrusive safety device that is a part of their daily wear and excites no comment. Outside of an athletic context, it may be seen as obtrusive (particularly to speech) and potentially embarrassing to wear, and thus be a harder sell.

RESEARCH STRATEGY

As we were unfamiliar with the term, we began our research by looking for information about "mouth-as-a-platform" technologies. However, a quick search for the term turned up only a handful of entries, and all of those either referred to a virtual reality simulator for dental training or to "word-of-mouth as a platform" for marketing.

From the context and the attached PowerPoint presentation in the project specs, we gathered that the real question before us is what "form factors" — that is, what shape and size device — could a patient reasonably be expected to wear for extended periods of time as, for example, a mouthguard to generate continuous data rather than taking one-time test samples of saliva. We therefore researched examples of other devices, preferably designed as sensors (rather than, for example, orthodontic work), meant to be held in the mouth for an extended period.

After some scattershot findings (including the nano-biosensors described in our findings above), we discovered a 2018 paper focused entirely on the subject of comfort in wearable sensors. This paper referred only to mouthguards as a tool for biometric monitoring of saliva; however, it also discussed form factors and comfort in general and so became the backbone of this report, especially since it extensively cited its own sources, giving us more original material to work with.

After pulling all the available data together (the sources cited being the representative sample), we found that while nano-biosensors have been tested, they have not yet reached the market. Nor, it seems, have biosensor mouthguards. Based on the available data, we have offered our hypothesis as to why at the end of our findings above.
Sources
Sources

From Part 01
Quotes
  • " 24 June 2019 GlaxoSmithKline plc today announced that TESARO, an oncology-focused business acquired by GSK, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZEJULA (niraparib). The application was granted priority review and has an action date of 24 October 2019."
  • "The sNDA supports a potential new indication for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with either: BRCA mutation or Homologous recombination deficiency (HRD) and have progressed more than six months after the last platinum-based chemotherapy."
  • "Mary Lynne Hedley, Ph.D., President and Chief Operating Officer of TESARO, said, “The results of the QUADRA study demonstrate that ZEJULA is active as a late-line treatment for patients beyond those with BRCA mutations. With this study, we continue to advance our mission to provide more patients with ovarian cancer an opportunity to benefit from treatment with ZEJULA.”"
  • "Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “We know ZEJULA plays an important role in helping women with ovarian cancer whose disease has progressed despite initial therapy. Our hope is that over time, our ongoing clinical trials will demonstrate that this medicine can benefit even more patients.”"
  • "QUADRA is a large multicenter, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients with relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who were treated with three or more previous chemotherapy regimens. "
  • "Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in three pivotal trials. TESARO is building a robust niraparib franchise by assessing activity across multiple tumor types and by evaluating several potential combinations of niraparib with other therapeutics."
  • "TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer. "
Quotes
  • " 06 June 2019 GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. "
  • "This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector."
  • "This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate. The original lyophilised powder version remains available for administration by a healthcare professional. "
  • "Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Nucala’s efficacy is well-established and this approval means that, for the first time, we are able to provide patients living with these debilitating conditions the option of receiving this important medicine in their own home.”"
  • "Tonya Winders, President, Global Allergy and Asthma Patient Platform (GAAPP), added: “People living with conditions like severe asthma often struggle to control their day-to-day symptoms, making routine activities like attending healthcare appointments a challenge. Empowering patients to take their medicines at home is an approach that has been successful in other chronic diseases such as diabetes and rheumatoid arthritis. GAAPP welcomes this approval for Nucala so it can be administered in a doctor’s office or in the convenience of a patient’s home.”"
  • "Following this approval, it is expected that the new administration options for Nucala will be available in the US shortly."
Quotes
  • " 23 May 2019 GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over "
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older. Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses."
  • "The approval is in response to last year’s inclusion of Shingrix on a list of 48 ‘clinically urgently needed new medicines’ in China designated for expedited review, reflecting the country’s prioritization of critical new prevention and treatment options."
  • "Shingles is caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox. Nearly all adults over 50 have the shingles virus dormant in their nervous system, waiting to reactivate with advancing age[i]. Shingles affects nearly three million adults in China annually[ii]."
  • "Dr. Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines said: “Today’s approval of Shingrix in China is recognition of the significant scientific advance this vaccine represents. In the pivotal studies the vaccine has shown over 90% efficacy across all age groups in the prevention of shingles, a disease that affects one in three people across the Asia-Pacific region[iii]. It can result in lasting pain and other complications which can severely impact the quality of people’s lives.”"
  • "Introduction of the vaccine into China will be phased, starting in 2020, to ensure consistent and reliable supply of the vaccine to all countries in which the vaccine has been launched. Over the next several years, GSK expects to increase supply of Shingrix globally and is investing in significant capacity expansion."
Quotes
  • " 08 April 2019 US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults "
  • "Approval based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, traditional, three-drug regimen through 48 weeks, with no cases of resistance.[1]"
  • "ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.[1]"
  • "Deborah Waterhouse, CEO, ViiV Healthcare, said: “Building on our innovative portfolio of medicines, Dovato is powered by dolutegravir, an antiretroviral included in multiple combination therapies and the most prescribed integrase inhibitor in the world,[2] coupled with the established profile of lamivudine. With Dovato, the first complete, single-tablet, two-drug regimen for treatment-naïve adults, ViiV Healthcare is delivering what patients are requesting—a chance to treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment.”"
  • "DTG/3TC as a complete, once-daily, single-tablet, two-drug regimen for HIV-1 therapy is currently under review by the European Medicines Agency (EMA) and regulatory authorities in Canada, Australia, Switzerland, and South Africa and several additional submissions are planned throughout 2019."
Quotes
  • " 29 April 2019 ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV. If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV."
  • "ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for the investigational, monthly, injectable, two-drug regimen of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine."
  • "The submission is based on the global ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies that included more than 1,100 patients from 16 countries and demonstrated the combination of cabotegravir and rilpivirine, injected monthly, was as effective as a standard of care, daily, oral, three-drug regimen in maintaining viral suppression throughout the 48-week study period. These results were presented in March at the 2019 Conference on Retroviruses and Opportunistic Infections."
  • "Deborah Waterhouse, CEO of ViiV Healthcare, said: “The long-acting, once-monthly, injectable regimen of cabotegravir and rilpivirine has the potential to give people living with HIV one month between doses with similar safety and efficacy as today’s standard of care – an oral three-drug regimen that has to be taken every day. ViiV Healthcare is proud to be at the forefront of this innovation in HIV treatment and we look forward to working with the FDA to provide people living with HIV in the US this novel option.”"
  • "ViiV Healthcare and Janssen plan to submit regulatory applications for the two-drug regimen of cabotegravir and rilpivirine to the European Medicines Agency, Health Canada and other global agencies in the coming months."
Quotes
  • " 26 April 2019 GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)"
  • "GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of Benlysta (belimumab), a B-lymphocyte stimulator (BLyS)-specific inhibitor, in children with lupus from as young as five years of age."
  • "Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK commented, “Children with lupus have had limited options available to help treat their condition. This accelerated decision means children in the US now have an innovative, FDA-approved medicine available to help manage the impact of living with this challenging autoimmune disease.”"
  • "Kenneth M Farber, President and CEO, Lupus Research Alliance, commented, “The go-ahead from the FDA for belimumab to be used to treat children with lupus is terrific news for a community desperate for more treatment options. As the only biologic approved for the disease, belimumab has been helping many adults with lupus, and now physicians will have another, much-needed tool for treating their pediatric patients.”"
  • "The approval extends the current indication in the US for the IV formulation of Benlysta in adults, to patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Benlysta was approved in the US in March 2011 for adults, and is currently the only medicine specifically approved in the US for both adults and children with SLE. The IV formulation of Benlysta is currently not approved for use in children anywhere else in the world although regulatory submissions are ongoing in other parts of the world."
Quotes
  • " 07 September 2018 GlaxoSmithKline plc (LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD), guided by blood eosinophil counts."
  • "The CRL states that more clinical data are required to support an approval. GSK will work closely with the FDA to determine the appropriate next steps for the supplementary biologics licence application (sBLA)."
  • "First approved in 2015 for severe eosinophilic asthma, and also licenced for EGPA in the US, mepolizumab is the first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils. Inhibiting IL-5 binding in this way reduces blood eosinophils."
  • "Mepolizumab has been studied in over 3000 patients in 16 clinical trials across a number of eosinophilic indications and is currently being investigated for severe hypereosinophilic syndrome and nasal polyposis, in addition to the sBLA filed for the treatment of patients with COPD."
Quotes
  • " 25 July 2018 GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines"
  • "Issued: Wednesday 25 July 2018 London UK and Mountain View, CA"
  • "Multi-year collaboration expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programmes "
  • "GSK and 23andMe today unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialisation expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries."
  • "Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said; “We are excited about this unique collaboration as we know that drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines. Partnering with 23andMe, an organisation whose vision and capabilities are transforming the understanding of how genes influence health, will help to shift our research and development organisation to be ‘driven by genetics’, and increase the impact GSK can have on patients.”"
Quotes
  • " 24 July 2018 GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK "
  • "GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), today announced the transition of the development programme for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, to GSK."
  • "Dr. Hal Barron, President R&D, GSK said, “The data we’ve seen for GSK ‘794 point to the potentially transformational nature of this T-cell therapy, as this is the first cell therapy to show clinical response in solid tumours. The concept of cells as medicines is an exciting component of our immuno-oncology portfolio and leverages our expertise in manufacturing T-cell therapies. This has been a productive collaboration on GSK ‘794 and we look forward to continued collaboration with Adaptimmune.”"
  • "GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognising with high affinity the tumour-specific antigen, NY-ESO. When the modified cells are re-infused into the patient, they recognise and kill tumour cells that express the NY-ESO antigen. NY-ESO is expressed at various levels across different tumours, and appears to be expressed at high levels in defined sub-types of soft tissue sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers."
Quotes
  • "20 July 2018 US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria P. vivax malaria marks a major contribution towards malaria eradication efforts"
  • "GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection."
  • "Dr. Hal Barron, Chief Scientific Officer and President of Research and Development, GSK, said: “Today’s approval of Krintafel, the first new treatment for Plasmodium vivax malaria in over 60 years, is a significant milestone for people living with this type of relapsing malaria. Together with our partner, Medicines for Malaria Venture, we believe Krintafel will be an important medicine for patients with malaria and contribute to the ongoing effort to eradicate this disease.”"
  • "Krintafel is an 8-aminoquinoline derivative with activity against all stages of the P. vivax lifecycle, including hypnozoites. It was first synthesised by scientists at the Walter Reed Army Institute of Research in 1978. GSK’s legacy in the research and development of tafenoquine as a potential medicine for malaria commenced over 20 years ago. In 2008, GSK entered into a collaboration with the not-for-profit drug research partnership, MMV, to develop tafenoquine as an anti-relapse medicine for patients infected with P. vivax. The tafenoquine clinical programme is part of GSK’s global health programme aimed at improving healthcare for vulnerable populations."
Quotes
  • " July 2018 US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria"
  • "GSK and Medicines for Malaria Venture (MMV) today announced that the Antimicrobial Drugs Advisory Committee (AMDAC) of the United States Food and Drug Administration (FDA) voted that there is substantial evidence of the effectiveness (13 for; 0 against) and adequate evidence of the safety (12 for; 1 against) of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax)malaria in patients 16 years of age and older."
  • "Pauline Williams, Head of Global Health R&D, GSK said: “After extensive efforts to develop a new treatment for patients with P. vivax malaria, working in collaboration with Medicines for Malaria Venture, we welcome this endorsement. If approved, tafenoquine would be the first new medicine for this indication in more than 60 years. Together with our partners, we look forward to the final decision by the FDA.”"
  • "Tafenoquine is not approved for use anywhere in the world. The new drug application (NDA) was submitted by GSK to the FDA in November 2017. A regulatory submission was also made to the Australian Therapeutic Goods Administration (TGA) in December 2017 with a decision anticipated in the next few months. Approvals of tafenoquine by the FDA and TGA would help support registrations in countries where P. vivax malaria is endemic, and would be first steps on the path to global adoption of the new medicine."
Quotes
  • "27 June 2018 Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules New, alternative 2+1 dosing schedule approved in Europe for Bexsero in infants"
  • "Healthcare professionals now have more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B, after European Commission approval of an alternative Bexsero (rDNA, component, adsorbed)1 immunisation schedule requiring one less injection."
  • "The reduced immunisation schedule for infants: two primary doses of Bexsero plus one booster dose, triggers a similar immune response as the existing 3+1 schedule."
  • "The EMA approval of this new option allows health care professionals and public health officials to continue using the existing 3+1 schedule or alternatively begin Bexsero vaccinations at 3 months of age with a minimum interval of 2 months between the first and second dose."
  • "“The reduced number of doses during the first year of life could increase compliance and may improve vaccination timing with more children up to date with their vaccination schedule,” said Dr. Federico Martinon-Torres, Head of Pediatrics at Hospital Clínico Universitario de Santiago and lead author of the study."
Quotes
  • "29 May 2018 GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD"
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease (COPD). This is the first regulatory filing to be made in Japan for a triple COPD therapy in a single inhaler."
  • "Dave Allen, Head, Respiratory Therapy Area R&D, GSK said: “COPD is a debilitating lung disease affecting over five million people in Japan. Many patients require combination treatment with different types of medicines to reduce both symptoms and exacerbations but there is currently no triple therapy available in Japan delivered in a single inhaler. If approved, once-daily FF/UMEC/VI delivered in the Ellipta would be an important innovation in the management of COPD in Japan alongside our current range of treatments.”1"
  • "The proposed indication is for the relief of various symptoms with COPD (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid, long-acting inhaled beta2-agonist and long-acting inhaled anticholinergic drug is required.)"
  • "Dr Ted Witek, Senior Vice President and Chief Scientific Officer at Innoviva added, “We are delighted to have filed a new drug application for the first single inhaler triple therapy for the treatment of COPD in Japan where the prevalence of COPD is of public concern. We look forward to a decision from the MHLW, which, if positive, would provide a new therapeutic option for appropriate patients with COPD in Japan.” "
Quotes
  • "05 February 2019 GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers"
  • "Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers"
  • "Merck KGaA, Darmstadt, Germany will receive an upfront payment of €300 million (£260 million) and is eligible for potential development milestone payments of up to €500 million (£440 million) triggered by data from the M7824 lung cancer programme, plus future approval and commercial milestones of up to €2.9 billion (£2.5 billion), for a total potential deal value of up to €3.7 billion (£3.2 billion)"
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance to jointly develop and commercialise M7824 (bintrafusp alfa*). M7824 is an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers. This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC)."
  • "M7824 is designed to simultaneously target two immuno-suppressive pathways, transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. Bifunctional antibodies aim to increase efficacy above and beyond that achieved with individual therapies or combinations of individual therapies.1 M7824 has the potential to offer new ways to fight difficult-to-treat cancers beyond the established PD-1/PD-L1 class. In addition to use as a single agent, M7824 is also being considered for use in combination with other assets from the pipelines of both companies."
Quotes
  • "19 December 2018 GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture"
  • "Transaction provides a unique opportunity to accelerate GSK’s strategy and create substantial value for shareholders Lays foundation for separation of GSK to create two new UK-based global companies focused on Pharmaceuticals/Vaccines and Consumer Healthcare"
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture, with combined sales of approximately £9.8 billion ($12.7 billion)[1]. GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity interest of 32% in the Joint Venture."
  • "The proposed all-equity transaction represents a compelling opportunity to build on the recent buyout of Novartis’ stake in GSK Consumer Healthcare, to create a new world-leading consumer healthcare business and to deliver further significant shareholder value. The proposed transaction also supports GSK’s key priority of strengthening its pharmaceuticals business over the next few years by increasing cashflows and providing an effective pathway through the separation of GSK Consumer Healthcare to build further support for investment in its R&D pipeline."
  • "The new Joint Venture will be well-positioned to deliver stronger sales, cash flow and earnings growth driven by category leading Power Brands, science-based innovation and substantial cost synergies. The combination will bring together two highly complementary portfolios of trusted consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s Advil, Centrum and Caltrate. The Joint Venture will be a category leader in Pain Relief, Respiratory, Vitamin and Mineral Supplements, Digestive Health, Skin Health and Therapeutic Oral Health. The Joint Venture will be the global leader in OTC products with a market share of 7.3% ahead of its nearest competitor at 4.1% and have number 1 or 2 market share positions in all key geographies, including the US and China."
Quotes
  • "22 January 2019 GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company"
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The transaction, which was announced on 3 December 2018, significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology."
  • "TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA). Zejula is currently approved in the US and Europe as a treatment for adult patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy, regardless of BRCA mutation or biomarker status."
  • "Clinical trials to assess the use of Zejula in “all-comers” patient populations, as a monotherapy and in combinations, for the significantly larger opportunity of first line maintenance treatment of ovarian cancer are also underway. These ongoing trials are evaluating the potential benefit of Zejula in patients who carry gBRCA mutations as well as the larger population of patients without gBRCA mutations whose tumours are HRD-positive and HRD-negative. Results from the first of these studies, PRIMA, are expected to be available in the second half of 2019."
  • "GSK also believes PARP inhibitors offer significant opportunities for use in the treatment of multiple cancer types. In addition to ovarian cancer, Zejula is currently being investigated for use as a possible treatment in lung, breast and prostate cancer, both as a monotherapy and in combination with other medicines, including with TESARO’s own anti-PD-1 antibody (dostarlimab, formerly known as TSR-042)."
  • "In addition to Zejula and dostarlimab, TESARO has several oncology assets in its pipeline including antibodies directed against TIM-3 and LAG-3 targets."
Quotes
  • "26 November 2018 Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare"
  • "ViiV Healthcare today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Juluca Combination Tablets (containing dolutegravir 50mg/rilpivirine 25mg) for the maintenance treatment of human immunodeficiency virus type 1 (HIV-1) infection."
  • "Juluca is a two-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide 2, and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).3 The distribution and sales operations of the once-daily single-pill regimen will be conducted by GlaxoSmithKline K.K. Tokyo, in the same way as for existing products of ViiV Healthcare in Japan. "
  • "Dustin Haines, President, ViiV Healthcare, Japan said, “This regulatory approval demonstrates our commitment to bringing new medicines for people living with HIV, as they now have the opportunity to maintain their viral suppression with only two drugs within a single-pill.”"
  • "The drug was filed for approval in Japan on 1 August 2018.1 Juluca received approval for the treatment of HIV infection in November 2017 4 in the US and in May 2018 in Europe.5"
  • "Dr. Ichiro Koga, MD, Director Medical Affairs, ViiV Healthcare, Japan said, “We have found a way to reduce the number of antiretrovirals whilst maintaining the efficacy of the traditional three-drug regimen, for people living with HIV. This innovative advancement supports our commitment to making HIV treatment a smaller part of people’s lives and demonstrates the potential of our robust clinical research programme.”"
Quotes
  • "22 November 2018 GSK and Kyowa Hakko Kirin sign strategic commercialisation deal in Japan for daprodustat, a potential new oral treatment for anaemia associated with chronic kidney disease"
  • "GSK and Kyowa Hakko Kirin Co., Ltd., today announced a strategic collaboration for the future commercialisation of daprodustat in Japan. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor currently in phase 3 development by GSK for the treatment of anaemia associated with chronic kidney disease (CKD)."
  • "This agreement recognises the importance of bringing this potential new medicine to patients in Japan and its joint nature brings together the global development and commercial expertise of GSK with the detailed CKD expertise of Kyowa Hakko Kirin. Under the terms of the agreement, GSK will be responsible for completion of the ongoing phase 3 clinical programme and regulatory submissions for marketing authorisation in Japan. Distribution of daprodustat will be exclusively conducted by Kyowa Hakko Kirin in the Japan market. Launch activities, including engagement of healthcare professionals and commercial activities, are expected to be conducted jointly by Kyowa Hakko Kirin and GSK. The financial details of the deal are not being disclosed."
  • "Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said, “We anticipate making a regulatory submission to the Japanese Ministry of Health, Labour and Welfare in 2019 and if approved, we believe daprodustat would be an important new oral treatment option for Japanese patients with anaemia associated with CKD. We look forward to working with Kyowa Hakko Kirin, given their extensive experience in this area, to successfully launch and commercialise daprodustat in Japan.”"
  • "In addition to the Japanese development programme, GSK has an ongoing global phase 3 registration programme, including: ASCEND-D (Anaemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis) will enrol approximately 3,000 dialysis dependent patients with anaemia associated with CKD switching from an erythropoietin-stimulating agent (ESA). Recruitment has completed, and results are anticipated in 2020 ASCEND-ND (Anaemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-Dialysis) will enrol approximately 4,500 non-dialysis dependent patients with anaemia associated with CKD, and will include patients either switching from or naive to an ESA. Recruitment remains ongoing and results are anticipated in 2020."
  • "Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the production of red blood cells and iron metabolism, similar to the physiological effects that occur in the body at high altitude. Daprodustat is not approved as a treatment for anaemia associated with CKD or any other indication anywhere in the world."
Quotes
  • "09 November 2018 Once-daily Trelegy Ellipta gains expanded COPD indication in Europe First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation."
  • "GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). "
  • "Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “We are pleased that the European Commission has approved the expanded use of Trelegy Ellipta as this will enable even more COPD patients to benefit from this important medicine.”"
  • "While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time. The expanded indication for Trelegy Ellipta reflects the evidence supporting its potential benefits in a broader group of patients than originally indicated, giving them the option of taking a once-daily single inhaler triple therapy for the first time."
  • "Dr. Paul Meunier, VP, Respiratory Medicine at Innoviva, added, “We are delighted that once-daily single inhaler triple therapy will now be available for COPD patients requiring a step up from dual bronchodilation, giving them a new option to help manage their disease.”"
  • "FF/UMEC/VI is the first COPD treatment to provide a combination of three molecules in a single inhaler that is taken in a single inhalation, once a day. It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines."
Quotes
  • "21 September 2018 Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria"
  • "Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries"
  • "GSK and Medicines for Malaria Venture (MMV) today announced that the Australian Therapeutics Good Administration (TGA) has approved single-dose Kozenis (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for the acute P. vivax infection."
  • "Anne Belcher, VP and General Manager GSK Australia, said: “We are delighted to have achieved approval for single-dose tafenoquine. In addition to providing a treatment option for P. vivax infected patients in Australia, the TGA approval of Kozenis will support regulatory submissions in P. vivax-endemic countries where there is significant unmet medical need for simple and effective therapies. Working with our partner, Medicines for Malaria Venture, our intent is to drive patient access in these countries by providing tafenoquine at an affordable price as part of global efforts to eradicate malaria.”"
  • "Kozenis is an 8-aminoquinoline derivative with activity against all stages of the P. vivax lifecycle, including hypnozoites. It was first synthesised by scientists at the Walter Reed Army Institute of Research in 1978. GSK’s legacy in the research and development of tafenoquine as a potential medicine for malaria commenced over 20 years ago. In 2008, GSK entered into a collaboration with the not-for-profit drug research partnership, MMV, to develop tafenoquine as an anti-relapse medicine for patients infected with P. vivax. The tafenoquine clinical programme is part of GSK’s global health programme aimed at improving healthcare for vulnerable populations."
Quotes
  • "Our Pharmaceuticals R&D organisation is focused on research across four therapy areas – two core areas where we already have strong leadership developing new medicines: Respiratory and HIV/infectious diseases; and two potential areas where we have ongoing development programmes: Oncology and immuno-inflammation."
  • "We also invest significantly in broader early discovery research, incubating areas of science outside our four core therapy areas where we think there is the potential to develop transformational medicines. This currently includes research into neuroscience and global health. "
  • "Our Vaccines R&D organisation is developing innovative vaccines which have the potential to help reduce the burden of many communicable diseases. At our three global R&D hubs in Belgium, Italy and the USA we’re researching vaccines against bacterial, viral and parasitic pathogens."
  • "Ninety percent of the vaccines in our pipeline are being developed in partnership with others. We have a long track record of collaborating with governments, healthcare providers, regulators, academic institutions, non-governmental organisations, vaccine producers and other key partners to tackle public health challenges around the world."
  • "Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health."
  • "Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. Our pipeline is fueled by five global innovation hubs that bring together our R&D, marketing and consumer insights teams, enabling us to develop innovative products based on the everyday healthcare needs of our consumers."
Quotes
  • "BARRIER-FORMING PRODUCTS We are seeking products that form a barrier (physical, chemical or otherwise) that maintains the health of the upper respiratory tract (nasal area and throat) with secondary interest in the lower airways. Minimum data requirement = proof of concept."
  • "ANTIOXIDANT/ANTI-INFLAMMATORY We are interested in nonprescription healthcare products that are focused on antioxidant/anti-inflammatory products that combat the reactive oxidative species (ROS), free radicals and/or inflammatory mediators caused by exposure to air pollution. "
  • "DIGITAL We are interested in connected devices that help consumers manage their respiratory health and the impact of air pollution. Areas of interest broadly include estimation of pollution exposure and symptom tracking. Minimum data requirement = proof of concept."
  • "DIGITAL HEALTH PLATFORMS We are interested in connected devices which help consumers manage their Respiratory conditions. Areas of interest broadly include diagnostics, medication compliance and symptom tracking for our Multi-symptom, Allergy, Decongestion and Smokers’ Health franchises."
  • "DIFFERENTIATED ORAL DOSAGE FORMS We are seeking differentiated oral dosage forms for our Multi-symptom, Allergy and Smokers’ Health franchises. This innovation may deliver superior efficacy or enhanced user experience. Minimum data requirement = proof of concept."
  • "NASAL SPRAY DELIVERY We are interested in innovation related to delivery of OTC medicines into the nasal cavity for our Allergy and Decongestion franchise. This innovation may deliver superior efficacy o"
  • "NEXT-GENERATION NICOTINE REPLACEMENT TRANSDERMAL TECHNOLOGY We are interested in innovative transdermal patch, topical, or device technologies that can provide superior nicotine delivery compared to currently marketed transdermal nicotine delivery patches."
  • "NEW PLAQUE-REDUCING OR PLAQUE-INHIBITING SOLUTIONS The buildup of dental plaque is the precursor for several oral diseases, including gum disease. In the early stages, this can lead to soreness, inflammation and bleeding of the gums on brushing. Therefore, we are seeking to develop products that help reverse the early signs of gum disease and "
  • "LONG-LASTING EFFICACY FOR OESOPHAGEAL REFLUX MANAGEMENT We are interested in products/technologies with clinical evidence for effectively managing the occurrence (frequency) and symptoms (severity) of oesophageal reflux and for providing consequential improvements in quality of life. We would like to see products with novel approaches or modes of action."
  • "TEMPORAL AND EFFICACY ASPECTS – PAIN RELIEF The consumer in pain needs an analgesic solution that works quickly and effectively, so any formulation technologies that enable a quicker onset of pain relief or that extend the duration of relief are of interest to us. We are also interested in technologies that provide the same pain relief at a lower dose."
  • "LOWER DIGESTIVE HEALTH SOLUTIONS We are interested in technologies that address common digestive disorders and/or manage their associated symptoms (eg, food intolerance, irritable bowel syndrome, constipation)."
Quotes
  • "Zejula (niraparib)† Type Poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor Indication First line maintenance ovarian cancer and other solid tumours Phase 3 Oncology"
  • "dostarlimab† Type Anti-Programmed Cell Death protein 1 receptor (PD-1) antibody Indication Ovarian cancer Phase 3 Oncology"
  • "Phase 2 Oncology Drugs dostarlimab† Type Anti-Programmed Cell Death protein 1 receptor (PD-1) antibody Indication Non-small cell lung cancer, MSI-H cancer (incl endometrial)* 2857916† Type B-cell maturation antigen antibody drug conjugate Indication Multiple myeloma* 3377794† Type NY-ESO-1 autologous engineered TCR-T cells (engineered TCR) Indication Sarcoma, solid and heme malignancies 3359609† Type Induced T-cell co-stimulator (ICOS) agonist antibody Indication Non-small cell lung cancer and solid tumours molibresib (525762) Type BET family bromodomain inhibitor Indication ER+ breast cancer, other solid tumours and haematological malignancies M7824† Type Transforming growth factor beta (TGFβ) trap and immune checkpoint (PD-1) inhibitor bispecific Indication Non-small cell lung cancer TSR-022† Type Anti-T-cell immunoglobulin and mucin domain-3 (TIM-3) antibody Indication Non-small cell lung cancer 3174998† Type OX40 agonist monoclonal antibody Indication Solid tumours and haematological malignancies"
  • "Phase 1/2 Oncology 3326595† Type Protein arginine methyltransferase 5 (PRMT5) inhibitor Indication Solid tumours, heme malignancies"
  • "Phase 1 Oncology 1795091 Type Toll-like receptor 4 (TLR4) agonist Indication Cancer 2636771 Type Phosphatidylinositol 3-kinase (PI3K) beta inhibitor Indication Cancer 3368715† Type Protein arginine methyltransferase 1 (PRMT1) inhibitor Indication Cancer 3145095 Type RIP1 kinase inhibitor Indication Pancreatic cancer and selected solid tumors 35371422 Type NY-ESO-1-targeting bispecific Indication Cancer TSR-033† Type Anti-lymphocyte activation gene-3 (LAG-3) antibody Indication Cancer"
  • "HIV/Infectious Diseases Submitted Dectova (zanamivir) i.v.† Type Neuraminidase inhibitor (i.v.) Indication Influenza MAA S: Nov17 dolutegravir + lamivudine Type HIV integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor (NRTI) Indication HIV infection MAA S: Sept18 NDA/BLA S: Oct18"
  • "Phase 3 HIV/Infectious dolutegravir + lamivudine Type HIV integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor (NRTI) Indication HIV infection MAA S: Sept18 NDA/BLA S: Oct18 III fostemsavir Type HIV attachment inhibitor Indication HIV infection cabotegravir + rilpivirine† Type HIV integrase strand transfer inhibitor + non-nucleoside reverse transcriptase inhibitor (NNRTI) (long-acting regimen) Indication HIV infection cabotegravir Type HIV integrase strand transfer inhibitor (long-acting) Indication HIV pre-exposure prophylaxis"
  • "Phase 2- HIV/Infectious cabotegravir Type HIV integrase strand transfer inhibitor (long-acting) Indication HIV pre-exposure prophylaxis II gepotidacin Type Type 2 topoisomerase inhibitor Indication Bacterial infections 32288361 Type HBV antisense oligonucleotide Indication Hepatitis B 33894041 Type HBV LICA antisense oligonucleotide Indication Hepatitis B 3640254 Type HIV maturation inhibitor Indication HIV infection"
  • "Phase 1- HIV/Infectious 3036656† Type Leucyl t-RNA synthetase inhibitor Indication Tuberculosis 3810109† Type HIV broadly neutralizing antibody Indication HIV infection"
  • "Immuno/Inflammation Phase 3 Benlysta + Rituxan† Type B lymphocyte stimulator monoclonal antibody (s.c.) + cluster of differentiation 20 (CD20) monoclonal antibody (i.v.) Indication Systemic lupus erythematosus"
  • "Immuno/Inflammation Phase 2 Benlysta + Rituxan† Type B lymphocyte stimulator monoclonal antibody (s.c.) + cluster of differentiation 20 (CD20) monoclonal antibody (i.v.) Indication Sjogren’s syndrome 3196165† Type Granulocyte macrophage colonystimulating factor monoclonal antibody Indication Rheumatoid arthritis 2982772 Type Receptor-interacting protein 1 (RIP1) kinase inhibitor Indication Psoriasis**, rheumatoid arthritis, ulcerative colitis 2330811 Type Oncostatin M (OSM) monoclonal antibody Indication Systemic sclerosis"
  • "Immuno/Inflammation Phase 1 2831781† Type Lymphocyte activation gene 3 (LAG3) protein monoclonal antibody Indication Ulcerative colitis 2983559 Type Receptor-interacting protein 2 (RIP2) kinase inhibitor Indication Inflammatory bowel diseases** 3358699† Type BET targeted inhibitor Indication Rheumatoid arthritis 3858279† Type CCL17 inhibitor Indication Pain in osteoarthritis"
  • "Respiratory Phase 3 mepolizumab Type Interleukin 5 (IL5) monoclonal antibody Indication hypereosinophilic syndrome and nasal polyposis fluticasone furoate + vilanterol† + umeclidinium Type Glucocorticoid agonist + long-acting beta2 agonist + muscarinic a cetylcholine antagonist Indication Asthma"
  • "Respiratory Phase 2 2586881† Type Recombinant human angiotensin converting enzyme 2 (rhACE2) Indication Acute lung injury** and pulmonary arterial hypertension 2862277 Type Tumour necrosis factor receptor-1 (TNFR1) domain antibody Indication Acute lung injury 3772847† Type Interleukin 33r (IL33r) monoclonal antibody Indication Asthma 2881078 Type Selective androgen receptor modulator Indication COPD muscle weakness"
  • "Respiratory Phase 1 nemiralisib Type Phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor Indication Activated PI3K delta syndrome 2292767 Type Phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor Indication Respiratory diseases** 3511294† Type Interleukin 5 (IL5) long-acting monoclonal antibody Indication Asthma"
  • "Complete Response Letter: Respiratory Complete response letter mepolizumab Type Interleukin 5 (IL5) monoclonal antibody Indication COPD NDA/BLA R: Sep18"
  • "Other - Approved Krintafel† (tafenoquine) Type 8-aminoquinoline Indication Plasmodium vivax malaria NDA/BLA A: Jul18"
  • "Other Phase 3 daprodustat (1278863) Type Prolyl hydroxylase inhibitor (oral) Indication Anaemia associated with chronic renal disease"
  • "Other Phase 2 oxytocin (inhaled)† Type Oxytocin Indication Postpartum hemorrhage linerixibat (2330672) Type Ileal bile acid transporter (IBAT) inhibitor Indication Cholestatic pruritus"
  • "Other Phase 1 3439171† Type Hematopoietic prostaglandin D2 (hPGD2) synthase inhibitor Indication Muscle repair"
  • "Vaccines Approved Shingrix† (Zoster Vaccine) Type Recombinant Indication Herpes Zoster prophylaxis MAA A:March 2018"
  • "Vaccines Phase 3 Shingrix† (Zoster Vaccine) Type Recombinant Indication Herpes Zoster prophylaxis for immunocompromised Rotarix Type Live attenuated, PCV (Porcine circovirus) free Indication Rotavirus prophylaxis III (US) Bexsero Type Recombinant Indication Meningococcal B disease prophylaxis in infants MMR Type Live attenuated Indication Measles, mumps, rubella prophylaxis"
  • "Vaccines Phase 2 COPD† Type Recombinant Indication Reduction of the frequency of moderate and severe acute exacerbations in COPD patients by targeting non-typeable Haemophilus influenzae and Moraxella catarrhalis Hepatitis C† Type Heterologous recombinant viral vectors Indication Hepatitis C virus prophylaxis: prevention of establishment of chronic infection Malaria next generation† Type Recombinant Indication Malaria prophylaxis (Plasmodium falciparum) Men ABCWY Type Recombinant – conjugated Indication Meningococcal A,B,C,W and Y disease prophylaxis in adolescents Menveo Liquid Type Conjugated Indication Meningococcal A,C,W and Y disease prophylaxis in adolescents Shigella† Type Conjugated and outer membrane Indication Shigella diarrhea prophylaxis Tuberculosis† Type Recombinant Indication Tuberculosis prophylaxis RSV† Type Replication-defective recombinant viral vector Indication Respiratory syncytial virus prophylaxis in paediatric population HIV† Type Recombinant proteins Indication HIV infection prophylaxis"
  • "Vaccines Phase 1/2 RSV† Type Replication-defective recombinant viral vector Indication Respiratory syncytial virus prophylaxis in older adult population RSV† Type Replication-defective recombinant viral vector Indication Respiratory syncytial virus prophylaxis in maternal population Flu universal† Type Universal inactivated split influenza vaccine Indication Flu disease prophylaxis with broad protection over multiple seasons"
From Part 05
Quotes
  • "Saliva is a perfect translational research tool and diagnostic medium which is being utilized as a part of novel approaches to give molecular biomarkers a variety of oral and systemic infections and conditions. The capacity to break down saliva to screen health conditions and diseases is an exceedingly alluring objective for oral health advancement and research. Saliva tests have been used to detect caries risk, periodontitis, breast cancer, oral cancer, salivary gland diseases, and systemic disorders such as hepatitis, HIV and HCV."
Quotes
  • "In the era of new diagnostic methods and treatment options, patient care is rapidly changing. Early detection is an emerging paradigm which seeks to decrease patient morbidity and mortality by detecting disease at a phase where it is easily treatable. Wong spoke about the exciting new opportunities to use saliva liquid biopsy for early assessment of lung cancer because of the clinical performance of cancer detection, non-invasive collection process and the ease of collecting, transporting and storing saliva."
Quotes
  • "Salivaomics includes five diagnostic alphabets proteins, mRNAs, miRNAs, metabolic compounds, and microbes offers substantial advantages because disease states may be accompanied by detectable changes in one, but not all, dimensions."
Quotes
  • "Even so, what is most impressive is that salivary biomarkers not only arise in correlation with oral disorders but also those of distal tissues and organs. This suggests that oral fluids may represent a substantial reservoir of molecular and microbial information capable of communicating the onset or presence of disease throughout the body. An initiative of the National Institute of Dental and Craniofacial Research created a roadmap to achieve these goals whereby, with the use of oral fluids as the diagnostic medium, it would become possible to scrutinize the health and/or disease status of patients."
From Part 06
Quotes
  • "ACADEMIC: University of Chicago, MRC Epidemiology Unit at Cambridge University, Broad Institute of MIT and Harvard, Stanford University "
  • "INDUSTRY: Alnylam Pharmaceuticals, Inc., Biogen. Genentech. Pfizer, P&G Beauty"
Quotes
  • "Color is the industry leading, genetics-driven platform that enables personalized care delivery to improve health at scale."
Quotes
  • "Comprehensive testing Color analyzes 30 genes known to impact hereditary cancer risk – including BRCA1 and BRCA2. Color’s custom software and expert team provide clinical-grade genetic testing at a fraction of the price."
Quotes
  • "AncestryDNA is a cutting edge DNA testing service that utilizes some of the latest autosomal testing technology to revolutionize the way you discover your family history. This service combines advanced DNA science with the world's largest online family history resource to predict your genetic ethnicity and help you find new family connections."
Quotes
  • "The company’s service will offer discreet panels to assess hormone and other biomarkers in saliva specimens, relieving laboratorians from the complexities inherent in biomarker testing in research settings. Three panels are available—a fertility panel, a stress panel, and a steroid panel—each offering a customized set of multiplexed tests for steroid hormones and certain cytokines. On request, Oasis may able to test for additional biomarkers of interest to the research community."
Quotes
  • "DiagnosTechs is committed to using the most effective technology available and over the last several years has made significant investments in new laboratory technology to refine and improve our testing standards. We employ several gold standard mass spectrometry technologies for quantification of a variety of clinically important analytes."
  • "Our Inductively Coupled Plasma Tandem Mass Spectrometer (ICP-MS/MS) provides DiagnosTechs the ability to perform elemental analysis in clinical specimens with unparalleled accuracy, precision, and detection."
From Part 08
From Part 09
From Part 10
From Part 11
Quotes
  • "At PARC, we champion the ‘entrepreneurial scientist’ – the rare breed of innovator who is passionate about deep research, ambitious with new ideas, and has the business intelligence to see their vision through. "
  • "Our culture is as unique as our workforce. We know diverse perspectives and life experiences are what fuels innovation. And, since innovation is core to what we do, we’re dedicated to creating an accepting and collaborative environment where everyone can bring their best selves to work."
  • "While we operate globally, we’re locally minded. Our social responsibility efforts see PARC contributing funding and time off for our employees to volunteer at their choice of non-profits. We also sponsor organizations such as Teens in Tech and the Computer History Museum."
  • "Since being established in 1970, PARC (then called Palo Alto Research Center) has been central to many of the most important technological breakthroughs of our time. Now we’re a strong team of scientists and support staff who are working across a series of Focus Areas that we believe are integral to the future of innovation. These are AI and Human-Machine Collaboration, Digital Design and Manufacturing, Novel Printing, Smart Devices, IoT and Machine Intelligence, and the Digital Workplace."
  • "PARC is located in the heart of Silicon Valley, which means we’re surrounded by the buzz of some of the best global enterprises, startups, VCs, universities and industrial design firms in the world. We operate globally, providing custom R&D services, technology, guidance and intellectual property to Fortune 500 and Global 1000 companies, startups, government agencies and partners."
Quotes
  • "A key PARC asset is our unique set of Cleanroom facilities which allow clients to develop novel prototype devices and technologies quickly and cost-effectively. We work closely with clients to develop new processes, build prototypes, and transition technology to manufacturing. "
  • "Design, Develop and Fabricate Novel Optoelectronic and Thin-Film Devices"
  • "Rapidly advance new projects from concept to production-ready Work with next-generation materials Create custom prototypes, even at low volumes Compete effectively in a rapidly evolving market Test, learn and iterate quickly and cost-effectively Reduce risk and control costs while focusing on your core business Optoelectronics Cleanroom and Resource Services"
  • "We have fully developed processes to design and fabricate a wide variety of active optoelectronic devices. Our facilities support sponsored R&D and product development for clients to prototype novel optical sources and systems that are transferable to manufacturers."
Quotes
  • "we’ve been pioneering developments, creating systems and devising solutions that improve the human experience of technology for almost half a century. We’re proud of our history of creative innovation, and we’re always looking to a future where our Focus Areas can be applied and achieved."
  • "Today, PARC provides custom R&D services, technology, expertise, best practice and intellectual property to a whole range of companies, from Fortune 500 and Global 1000 firms to startups and government agencies all over the world. With our help, organizations can reduce risk, accelerate their time to market and create new opportunities that would otherwise not exist."
  • "1970: Xerox PARC Founded Xerox Corporation assembles a team of world-class experts in information and physical sciences to become what is known as ‘The Architects of Information.’ The company establishes the Xerox Palo Alto Research Center (Xerox PARC) under the direction of Dr. George Pake. The charter for Xerox PARC is to create ‘The Office of the Future."
  • "1971: Laser printing- Xerox PARC modulates a laser to create a bit-mapped electronic image on a xerographic copier drum. "
  • "1972: Object-oriented programming- Xerox PARC designs Smalltalk – an object-oriented programming language that enables programs to be improved without being entirely rewritten. This innovation revolutionizes the software industry and influences subsequent programming systems."
  • "1973: Alto PC The Xerox Alto personal workstation is created. Its client-server architecture means computing is no longer restricted to the hierarchical world of large, centralized mainframes. This evolving PC will subsequently employ the world’s first bit-mapped display, graphical user interface with windows and icons, WYSIWYG (What You See is What You Get) editor, local area network/file storage, and commercial mouse. "
  • "1973: Ethernet An internal memo proposes a system of linking workstations, files, and printers together using a coaxial cable within a local area network"
  • "1973: Superpaint frame buffer Xerox PARC computer scientists record the first video image on the first computer paint system – a graphics program and framebuffer computer. "
  • "1974: WYSIWYG Xerox PARC coins the phrase to describe cut-and-paste bit-mapped editing: What You See Is What You Get (also known as ‘wizzy-wig’). This year, Xerox PARC also demonstrates the seminal Bravo word processing program (which leads to Microsoft Word) and device-independent imaging (which leads to Page Description Languages and influences subsequent design of Postscript)."
  • "1975: Graphical user interface (GUI) Xerox PARC debuts the first GUI, which uses icons, pop-up menus, and overlapping windows that can be controlled easily using a point-and-click technique. "
  • "1977: VLSI circuit design Xerox PARC (with Caltech) defines a new representation of Very Large Scale Integration (VLSI) circuit design."
  • "1979: Corporate ethnography PARC pioneers the use of ethnography for human-centered technology design, work practice redesign, and more."
  • "1979: Natural language processing To enable spell-checking, dictionary, and other tools, Xerox PARC invents computational linguistic technologies based on understanding the structure of language"
  • "1980: Optical storage Non-erasable, magneto-optical storage device technology is developed at Xerox PARC. Initially, its purpose is to enable high-speed data access on the Palo Alto campus. Eventually, it becomes commercialized through Optimem (which evolves into Cipher Data Products)."
  • "1980: Programming languages Xerox files the software copyright for Smalltalk-80. It’s one of only three software copyrights in existence"
  • "1982: Fiber optics The first optical cable-based local area network is operational. "
  • "1983: a-Si for printing A one-inch array of amorphous silicon (a-Si), thin-film transistors is used to drive a small Corjet ionographic printhead. This technology enables Xerox to offer lower cost multifunction machines"
  • "1986: Multi-beam lasers Xerox PARC is home to the world’s first dual-beam lasers. These print twice as fast as single beams"
  • "1987: Unicode/multilingual computing Xerox PARC designs a 16-bit coding system to represent any world script – in documents, user names, file names, or network services – in any combination with a single encoding"
  • "1988: Ubiquitous computing The term ‘ubiquitous computing’ is coined at Xerox PARC to describe a future where people seamlessly access resources and control environments using mobile devices"
  • "1989: Embedded data glyphs After inventing data glyphs, Xerox PARC pioneers the development of embedded data schemes that transform paper, and other surfaces, into computer-readable interfaces. "
  • "1989: Information visualization Taking a unique approach to the visualization of information, Xerox PARC invents techniques that use human perceptual and cognitive capacities to help people make sense of large amounts of diverse information. "
  • "1990: a-Si displays and digital x-ray imaging Xerox PARC builds the first x-ray imager using amorphous silicon. "
  • "1990: Multi-user virtual world Xerox PARC creates LamdaMOO, one of the oldest continuously operating real-time multi-user ‘dungeons’ or online environments. "
  • "1992: Collaborative filtering Collaborative filtering is implemented at Xerox PARC, inspired by the idea to involve human input (such as past user preferences and collaborators’ feedback) in helping information systems auto-filter content"
  • "1992: Internet standards The MBone Multicast backbone is co-founded and first implemented at Xerox PARC to deliver real-time multimedia over the Internet. "
  • "1997: Blue laser Xerox becomes the first printing company to create a blue laser. The reduced wavelength of a blue laser ultimately allows much higher resolution printing than is possible with the standard red and infrared lasers."
  • "2000: Electronic reusable paper A thin, flexible and portable document display technology invented at Xerox PARC. It looks and feels like paper; however, it can display different text and graphics when an electric charge is applied to it."
  • "2000 Digital Rights Management (DRM) Xerox PARC’s concepts for trusted systems and digital property rights lead to the joint venture called ContentGuard. "
  • "2001: Biomedical systems Xerox PARC partners with The Scripps Research Institute to develop instrumentation and information systems for accelerating discovery in the life sciences. In 2002, PARC demonstrates an operational prototype of the Fiber Array Scanning Technology Cytometer for screening blood samples about 1,000 times faster than automated digital microscopy."
  • "2002: PARC, a Xerox Company To broaden PARC’s ability to innovate, build breakthrough technology platforms, and develop business concepts for many different organizations, PARC is established as an independent company."
  • "2007: Powerset deal PARC and language search company Powerset sign an exclusive deal to commercialize breakthrough technology in consumer search"
  • "2010: PARC spins out PowerCloud systems Walden Venture Capital and Javelin Venture Partners join with PARC to spin-out PowerCloud Systems, focused on offering cloud-managed networking solutions for small and medium-sized businesses."
  • "2010: Thinfilm works with PARC Advanced printed memory provider, Thinfilm, partners with PARC to develop next-generation printed memory solutions. "
  • "2017: PARC spins off Metawave PARC reveals its intention to spin off wireless technology startup, Metawave, which builds technology solutions based on engineered metamaterials and Artificial Intelligence (AI) to commercialize smart beamsteering antenna systems for "
Quotes
  • "At PARC, our work is centered around a series of Focus Areas that we believe are the future of technology. Together, these are how we turn scientific creativity into real innovation that improves the experience of technology for people, businesses and government organizations around the world."
  • "Our Focus Areas are led by experts with a diverse range of capabilities and experiences, all of which are linked to our Competencies. Explore a Focus Area to find out more, and to read case studies and stories about how PARC is making a difference today."
Quotes
  • "PARC’s work in Artificial Intelligence (AI) and Human-Machine Collaboration is at the forefront of a new, transformative era of machine intelligence. This new breed of intelligent systems is characterized by trust and understanding, creating a path for autonomous and self-learning systems to play an ever more important and collaborative role in our everyday lives."
Quotes
  • "Central to this change in how we live and work will be Artificial Intelligence and the Internet of Things. Because of our work in these areas, PARC is one of the key drivers in making the Digital Workplace happen. We are working with clients to integrate the physical and digital worlds to improve the flow of work through conversational intelligent assistants, augmented reality, sensors, and analytics-driven services that enable responsive and reconfigurable spaces."
Quotes
  • "On-demand printing, industrial printing, flexible electronics and additive manufacturing are rapidly growing areas that will be part of the commercial and technological future of many businesses, startups and government organizations. Each of these markets is rapidly expanding, with growth spurred by recent innovative developments."
  • "In addition to applying existing and novel print technologies to new domains, PARC is continuing its development science for printers, materials, and novel processes. Combined, our ambitious work will satisfy the accelerating need for customization, personal experiences and previously unavailable products that companies and government agencies want to deliver."
Quotes
  • "The fourth industrial revolution is on its way, and IoT (Internet of Things) and Machine Intelligence are driving it. Thanks to easier connectivity and better analytics, businesses are now moving their physical systems towards an IoT-empowered digital world."
  • "At PARC, we’re working with clients and partners to develop the technologies that can enable this mass transition. With analytics front of mind, our labs are creating smart sensors and systems that enable rapid, reliable and secure data collection at scale. This data can then be used to develop actionable insights, or as the backbone of systems that will be at the forefront of a rapidly changing technology landscape."
Quotes
  • "For Cutting-Edge Manufacturing Technology Computer science has the potential to vastly improve how manufacturing and product design technologies work. Through innovations in Artificial Intelligence (AI), integrated planning and control, and additive manufacturing, organizations can create a greater variety of products and dramatically lower the time required to design complex engineered systems. In doing so, they can bring about a new age of customization and personalization."
  • "PARC scientists are working at the cutting edge of Digital Design and Manufacturing. We are creating a new science of computational design by inventing new representations and algorithms to design, analyze and plan the manufacture of highly complex structures that can be fabricated with state-of-the-art technology. "
  • "Our interdisciplinary work unifies principles of computational physics, geometric reasoning, automated spatial planning, and field modeling to help engineers create entirely new kinds of products – the likes of which many have not yet imagined."
Quotes
  • "Microsystems and Smart Devices The smartphone has made computing resources that were once only available in specialized environments open to everyone. At PARC, we believe the next generation of technologies to follow will provide people with capabilities that were once accessible only in laboratories."
  • "To make our vision a reality, PARC scientists take important hardware systems, like sensors, actuators, displays and cameras, and reinvent them to be accessible and versatile for use in a number of different advanced technologies that make a difference to our lives. Every piece of hardware is designed with size, form, factor, affordability, manufacturability and usability in mind, often combined with smart analytics."
Quotes
  • "Located in Silicon Valley, PARC is a renowned Open Innovation company that’s been at the heart of some of the most important technological breakthroughs of our time. We bring leading scientists, engineers and designers together to form bespoke teams across a series of Focus Areas that we believe are the future of technology, science and innovation."
  • "Creativity and science are core to PARC’s mission to reduce the time and risk attached to innovation. We draw on our revered history and our energy for the future to create technologies that improve our world and solve complex challenges."
  • "PARC was founded in 1970 as Xerox PARC. In 2002, PARC was incorporated, creating a wholly owned, independent subsidiary of Xerox Corporation. Since its inception, PARC has created $1 trillion in new industries, $60 billion in startups and spin-offs, and almost 6,000 patents and patent applications."
  • "The mission of PARC is essentially to create the Open Innovation center of the 21st century. We’re in the business of breakthrough innovation. That requires the ability to translate science into market impact. And that’s what we’ve been doing for many years.” Tolga Kurtoglu, CEO, PARC"
Quotes
  • "To help improve train efficiency and safety for the six billion passengers that use JR East services every year, the company turned to Palo Alto Research Centre (PARC), an open innovation company based in Silicon Valley focused on predictive analytics using the industrial internet of things (IIoT)."
  • "“Many of Japan’s capital-intense rail assets were deployed decades ago and JR East would obviously like to extract the maximum life out of them without compromising on safety,” says PARC strategic execution director Ajay Raghavan. “The shrinking population means that rail revenues are declining and so there is also pressure on O&M teams to be lean, plus a lot of more experienced technicians are beginning to retire."
  • "“They were getting 70%–80% success but not enough for the operations and maintenance teams to be sufficiently confident with the capabilities,” says Raghavan. “They were also sceptical about CBM.”"
  • "PARC deployed its MOXI™ technology suite, which utilises model-based algorithms that enable 90% or higher accuracy and low false alarm rates, and in some cases require only minimal data sets."
  • "“So this was of huge importance to JR East because the company prides itself on being on time, all the time. Within a matter of five months our PARC team was able to demonstrate first proof of concept of our predictive CBM working for the train door system with 95% accuracy or higher in classifying the different types of faults and, thanks to our algorithms, very low to minimum false alarm rates.”"
Quotes
  • "PARC Secures Two CalSEED Awards to Improve Energy Storage and Air Quality Palo Alto, CA: PARC, a Xerox company, today announced it won two awards from the California Energy Commission through the California Clean Energy Fund’s CalSEED grant program earlier this year. PARC will develop 1) a desalination battery for simultaneous desalination and electrical load-shifting, and 2) membrane-based electrochemical CO2 removal system for HVAC savings and increased occupant health and productivity."
  • "Desalination Battery: PARC is developing a novel desalination battery that combines the ability to desalinate highly saline waters with the ability to store electrical energy"
  • "Membrane-based Electrochemical CO2 Removal System: PARC is developing a simple retrofit to existing HVAC systems to improve indoor air quality while greatly reducing energy use and increasing occupant productivity"
Quotes
  • "Palo Alto, CA: PARC, a Xerox company, today announced its partnership with Blue Origin to enhance awareness and interest in the vast possibilities made possible by conducting R&D in space. The partnership will leverage PARC’s expertise in technology innovation and Blue Origin’s reusable suborbital rocket, New Shepard, to push new frontiers in four areas of technology R&D: advanced manufacturing, energy systems, human-machine interaction, and predictive analytics."
  • "The two will work together in “Accelerating Research in Space” (ARIS) to market joint R&D opportunities to PARC’s global 1000 partners and government agencies. The ultimate goal is to include an advanced technology R&D experiment on one of Blue Origin’s upcoming suborbital flights."
Quotes
  • "November 13, 2017, Palo Alto, CA: DataLase, the market leader in inline digital printing of products and packaging, and PARC, a Xerox company, announced a strategic partnership and lease signing agreement. The companies will work together to develop cutting-edge photonic printing solutions based on the DataLase award-winning, laser-reactive, color-change pigment technologies"
  • "The deal will accelerate the development of new laser-based hardware solutions that are optimized for use with DataLase color-change pigment technology to digitally print on a variety of products and packaging."
  • "DataLase, a SATO company, will collaborate with PARC to specifically advance its inkless multi-color Infinity technology platform, and has signed a lease agreement to establish a development office and innovation suite to operate inside the PARC facility in Palo Alto, CA."
Quotes
  • "November 8, 2017: Palo Alto, CA — PARC, a Xerox company, today announced it has accepted an award by the U.S. Department of Energy’s Office of Electricity Delivery and Energy Reliability (OE) to develop, prototype, and demonstrate TRANSENSOR, a low-cost optically based smart monitoring system along with Consolidated Edison Company of New York (Con Edison), and General Electric (GE)."
  • "TRANSENSOR (Transformer Real-time Assessment INtelligent System with Embedded Network of Sensors and Optical Readout) will increase reliability and safety by providing real time asset health."
  • "As part of the Energy Department’s commitment to a reliable and resilient power grid, the OE is investing nearly $10 million in early-stage research to help utilities inform decisions about increased deployment of DERs such as solar photovoltaics, plug-in electric vehicles, combustion engines, and energy storage systems on the grid."
Quotes
  • "October 30, 2017: Palo Alto, CA — FlexTech, a SEMI Strategic Association Partner announced a new development project with PARC, a Xerox company, to develop a hybrid, highly bendable, paper-like smart tag, incorporating a thin audio speaker. The product is aimed at applications in packaging, wearables prosthetics, soft robotics, smart tags, and smart cities and homes."
  • "SEMI-FlexTech Selects PARC to Build Ultra-Thin, Flexible Audio Speaker"
  • "PARC will use ink jet printing to build prototypes of the paper-like smart tags capable of producing audio signals, on a silver-printed polyethylene naphthalene (PEN) or polyimide (PI) substrate. They will develop and demonstrate a process for bonding chips, and printing active and passive components, as well as interconnects on the flexible substrate, essential in meeting the project goals for ruggedness and form factor. PARC will also focus on printing actuators to create thin film audio speakers. The technology will enable custom systems to be built on demand."
Quotes
  • "Norwalk, Conn., August 21, 2017 — Xerox Corporation (NYSE: XRX) and PARC, A Xerox Company, will partner with the Innovation Lab, an Innovation Institute company, to tackle health care challenges through collaboration in medical technology, engineering and robotics."
  • "“The idea behind the partnership is to bring together an organization well versed in advanced technology, such as printed electronics, machine learning and artificial intelligence, and combine it with a group that works with physicians, employees, and industry partners”, said Steve Hoover, Xerox CTO. “Together we will develop new products, ideas, and concepts that can be commercialized to reduce costs and transform health care delivery.”"
  • "“Working side-by-side with the pioneers of many technology platforms that have helped create new industries – from the Ethernet and laser printing to the graphic user interface and ubiquitous computing brings us world-renowned expertise,” said Larry Stofko, executive vice president of the Innovation Lab. “Our alliance with Xerox and PARC will enable us to galvanize breakthroughs in health care.”"
Quotes
  • "PARC to Develop Explainable Artificial Intelligence (XAI) Science for DARPA Palo Alto, California — PARC, a Xerox company, today announced it has been selected by the Defense Advanced Research Projects Agency (DARPA), under its Explainable Artificial Intelligence (XAI) program, to help advance the underlying science of AI. For this multi-million dollar contract, PARC will aim to develop a highly interactive sense-making system called COGLE (COmmon Ground Learning and Explanation), which may explain the learned performance capabilities of autonomous systems to human users."
  • "The key idea behind COGLE is to establish common ground between concepts and abstractions used by humans and the capabilities learned by a machine. These learned representations would then be exposed to the human via COGLE’s rich sense-making interface, enabling people to understand and predict the behavior of an autonomous system."
  • "For the DARPA project, COGLE will be developed using an autonomous Unmanned Aircraft System (UAS) test bed."
Quotes
  • "DARPA Chooses PARC, Siemens, Georgia Institute of Technology, and Michigan State University to Develop Modeling Tools to Transform State-of-the-Art Manufacturing"
  • "Palo Alto, California — PARC, a Xerox company, today announced it has been chosen as part of a team of organizations — including Siemens, Georgia Institute of Technology (GT), and Michigan State University (MSU) — by the DARPA TRAansformative DESign (TRADES) program. The goal of the multimillion dollar project is to develop a new digital modeling technology that will expand existing computer-aided design (CAD) software to design incredibly complex objects with superior functional properties that can still be manufactured with current manufacturing processes."
  • "“This project will have significant impact for high-performance products in specialized industries such as aerospace, defense, automotive, energy production, manufacturing tooling, medical devices and consumer products,” said Dr. Suraj Musuvathy, Senior Scientist, Siemens Corporate Technology"
  • "Unlike many CAD systems, Siemens’ NX™ software includes highly advanced features for the design of heterogeneous materials, composites and lattice structures, as well as preparation for additive manufacturing. Through the DARPA TRADES project, this team aims to further expand those capabilities to create a new approach for designing models with billions of geometric attributes and manufacturing these highly complex objects."
Quotes
  • "Experienced Collaboration to Break Down Boundaries of Predictive Modeling of Complex Systems"
  • "PALO ALTO, CALIF., APRIL 16, 2019 – PARC, a Xerox company, today announced it has been selected, alongside University at Buffalo, for a DARPA project to develop novel hybrid methods that combine multi-physics, equation-based models with data-driven machine learning models [such as Deep Neural Networks (DNNs)] to enable predictive modeling of complex systems in the presence of imperfect models and sparse and noisy data."
  • "DARPA, whose mission is to identify and pursue high-risk, high-payoff research initiatives for national security across a broad spectrum of science and engineering disciplines, is funding this project to address the serious limitations of purely data-driven methods. This research will lead to innovative hybrid methods, especially in studying physically-grounded systems that integrate a systematic understanding of the physics of the systems with data-driven machine learning approaches. "
  • "“We’re teaching physics to AI systems,” said the grant’s principal investigator Rahul Rai, PhD, associate professor of mechanical and aerospace engineering in UB’s School of Engineering and Applied Sciences. “We are developing hybrid methods that integrate physics-based models — these are math-based formulas that explain the world around us, such as Einstein’s E=MC2 — into the algorithms that guide machine learning, deep learning and other data-driven AI systems,” he said."
Quotes
  • "The Palo Alto Research Center, Inc. (PARC, a Xerox company) and George Mason University (GMU) have been awarded a contract from the Defense Advanced Research Project Agency (DARPA) Configuration Security program (ConSec). Within ConSec, researchers from PARC and GMU will collaborate on a project christened SCIBORG: Secure Configurations for the Internet of Things (IoT) based on Optimization and Reasoning on Graphs. The goal of SCIBORG is to devise fundamentally new approaches to determine security configurations that protect critical infrastructure and IoT-based systems. "
  • "“SCIBORG will measure its success in terms of the reduction of the impact of potential attacks. To reason about the security of an IoT configuration, it is important to evaluate the attack paths that are available to the adversary,” said Hamed Soroush, Senior Researcher at PARC and the Principal Investigator. “Configuration settings that reduce the impact of these attack paths would, by this line of reasoning, be more secure.” "
Quotes
  • "Printed Methane Sensors Project Honored in Technical Development Materials Category"
  • "NOVEMBER 15, 2018 – PALO ALTO, CALIF.— PARC, a Xerox company, today announced that its Printed Methane Sensors project has won an IDTechEx Technical Development Materials Award. The inaugural program honors the most significant technical development over the last 24 months in the field of material development."
  • "PARC developed a low-power, low-cost, leak-detection system for methane based on arrays of printed modified carbon nanotube sensor elements that operate at ambient temperature and humidity. The sensor materials developed by PARC and NASA Ames Research Center enable printed-carbon nanotube methane sensors to be used outside of the laboratory. This breakthrough promises to enable the graduation of printed carbon nanotube-based gas sensors from laboratory demonstrations to practical products. "
Quotes
  • "U.S. Department of Energy Selects PARC to Develop Low-Cost CO2 Sensors"
  • "August 14, 2018 – Palo Alto, Calif.— PARC, a Xerox company, was selected via a Funding Opportunity Award from the Department of Energy to develop low-cost CO2 sensors to improve indoor air quality and energy efficiency within buildings. The PARC project is funded by DOE’s Office of Energy Efficiency and Renewable Energy (EERE) through its Building Technologies Office (BTO), which announced in August 2017 its investment of up to $15.8 million in 13 projects that will drive innovation in early-stage R&D for advanced building technologies and systems that will serve as a foundation for future technological developments and reductions in building energy consumption."
  • "For this DOE-funded project, PARC will produce a low-cost, printed sorbent that measures CO2 via physical adsorption. The sensor heats up as a result of the CO2 adsorption, and PARC measures the heat produced to determine the levels of CO2. The goal of the research effort is to develop a low-cost sensor with a sensitivity of 50ppm."
  • "The Internet of Things (IoT) enables a myriad of solutions to help us sense and interpret the world. Printing is a promising approach to mass-produce and customize sensor systems to support the fast growing IoT. The low-cost, flexible form factor, and simple installation of PARC’s approach is ideal for a variety of applications including building efficiency, air quality, smart cities, industrial and residential safety, and wearables"
Quotes
  • "Nuremberg, Germany / Palo Alto, CA – Leoni, a global provider of energy and data management solutions in the automotive sector and other industries, and the research and development company PARC, a Xerox company, providing cutting-edge innovation for nearly 50 years, today announced a strategic partnership that will enable Leoni’s digitalization solutions. With the support of PARC’s groundbreaking technologies in the fields of condition-based maintenance (CBM), system analysis, artificial intelligence (AI) and embedded sensor technology, Leoni will drive its digital transformation forward. Initial research work is focused on the enablement of Leoni’s smart cable systems."
Quotes
  • "Palo Alto, CA: PARC, a Xerox company, today announced it has been selected, in partnership with University of Wisconsin-Madison, by DARPA, for a project in the Engineering Fundamental Design (FUN DESIGN) program. DARPA, whose mission is to identify and pursue high-risk, high-payoff research initiatives for national security across a broad spectrum of science and engineering disciplines, announced the first programs under its new Disruptioneering effort in August 2017. The new program pushes for faster identification and exploration of bold and risky ideas with the goal of accelerating scientific discovery."
  • "To advance the goal of the program, PARC and UW-Madison will develop Design by Function-sharing thrOugh Compositional qUalitative Synthesis (D-FOCUS), an entirely new mathematical framework for systematic conceptual design of complex mechanical assemblies such as vehicles and aircraft. This advancement in science will enable the systematic search for a topological layout (i.e., structure or form) that fulfills functional requirements that can be instantiated into models to generate preliminary, detailed, and optimal designs"
Quotes
  • "PARC has developed a breakthrough “wavelength shift detector” technology capable of monitoring light sources and reading signals from wavelength-encoded optical sensors with unprecedented resolution in a compact, low-cost unit. The PARC technology is applicable for interrogating fiber optic (FO) sensors (e.g., fiber Bragg grating sensors) as well as colorimetric sensors."
Quotes
  • "Many health conditions are caused by unhealthy lifestyles and can be improved by behavior change. Traditional behavior-change methods, like weight loss clinics or personal trainers, have obvious scalability issues in providing expert personalized daily support to large populations for long periods. "
  • "There’s a pressing need to extend the reach and intensity of existing successful health behavior change approaches. Personalized smartphone apps offer an excellent opportunity to deliver effective interventions for behavior change into everyday life at great scale. Smartphones also provide an opportunity to collect rich, fine-grained data necessary for understanding and predicting behavior-change dynamics in people going about their everyday lives. "
  • "Fittle is a new behavior-change smartphone app which delivers ecological momentary interventions and group support to help people progressively master healthy habits. PARC’s Fittle technology was developed over several years by our experts in AI, machine learning and behavioral economics."
  • "Fittle is designed to integrate different behavioral change strategies such as prompting, feedback and reward, and tracking and logging, to less prescriptive ones, such as social influence. Fittle integrates and applies theory and methods from mobile sensing, cognitive tutoring, and evidence-based social design to solve the problem of providing socially supported, autonomously planned and personalized ecological momentary interventions to help people achieve healthy behavior changes in diet and physical activity."
Quotes
  • "Hyperspectral imaging (HSI) refers to the ability to acquire a full optical spectrum at each point in an image. Whereas a color camera can only capture the intensity of incoming light in one of three colors—red, green and blue—a hyperspectral camera also captures the wavelengths of the light reflected from each point in a scene. Therefore, the move from color to full hyperspectral imaging yields exponentially more information, with tremendous value potential for myriad applications."
  • "1. Complete camera prototype Applications • Agriculture • Medicine • Security and defense • Autonomous vehicles • Consumer smartphones"
  • "PARC is actively working to enable the hyperspectral imaging ecosystem with PARC’s hyperspectral imaging technology, which is the only such technology with the size, weight, cost and performance suitable for mass-market adoption. Based on an elegant reversal of the operating principle of a liquid-crystal display, the PARC technology relies on a liquid-crystal layer about as thick as a human hair to encode hyperspectral information. It can therefore be integrated anywhere image sensors are currently used, including on smartphones."
Quotes
  • "Hipergraph The rise of sensors and computational power has led to the collection and storage of big data sets with multi-dimensional, complex relationships. This new generation of data not only requires innovative databases, but efficient algorithms to analyze."
  • "The challenge has been how to efficiently analyze complex data sets using less computational power as we have in raspberry Pi. Hipergraph, the high-performing graph analytics engine, was developed by PARC to tackle this problem. Hipergraph enables customer data to be processed quickly, simply and at low cost. As performance and memory capacity of servers continues to grow, most customer datasets can be processed without the significant performance and cost penalties inherent in big data clusters. PARC has developed its Hipergraph algorithms over the last few years in the domains of artificial intelligence (AI) and graph analytics. Hipergraph is relevant to clients with large, multi-dimensional datasets requiring fast, memory-efficient algorithms."
Quotes
  • "Hand-Held Flow Cytometer Flow cytometry is a method commonly used in clinical and research settings to examine the characteristics of biological cells. The bio-particles are guided one by one through a focused laser beam with sheath fluid and are characterized by fluorescence and light scattering. Currently, flow cytometers are large, expensive and often located in centralized laboratories. PARC’s “spatially modulated emission” technique enables a hand-held flow cytometer for high-performance onsite diagnostics at low cost, while maintaining testing speed and high signal-to-noise discrimination."
Quotes
  • "PARC has developed the Filament Extension Atomizer (FEA) to address problems arising from difficult-to-spray materials. Conventional spray methods work well for an ideal set of fluids, but often fail to maintain their quality as a spray becomes more difficult. FEA allows spraying of a wider range of fluids that are strain hardening due to presence of macromolecular components or simply high viscosity. The technology is capable of spraying a wide range of strain-hardening, non-Newtonian and high-viscosity fluids with tight particle size distributions, tunable droplet sizes, and at a large range of scales depending on the application."
  • "Applications: Consumer applications Drug delivery Spray coating Particle creation Spray drying Large area coating Painting Food processing Manufacturing"
Quotes
  • "Design feedback for additive manufacturing Using additive manufacturing to produce complex shapes that are otherwise hard to fabricate has led to the misconception that any 3D model can be identically 3D printed. Analyzing manufacturability in terms of printable geometry allows designers to make informed tradeoffs between design complexity and manufacturing capability."
  • "PARC’s web-based Makesim technology introduces novel geometric reasoning techniques to automatically plan, simulate and visualize the output of the 3D printing process as a solid model which can be inspected virtually and redesigned"
Quotes
  • "The cooling of living and working spaces requires a lot of energy – building cooling in the US alone accounts for 4.3 quads per year. There’s a dire need for innovative cooling solutions that could lead to greater energy savings. PARC has developed a “self-cooling” paint that cools down any surface up to 10 ºC (18 ºF) below ambient air temperature. This is accomplished by engineering a paint combining a high solar reflectance with a high emittance in the sky transparency window."
  • "Compared to competing passive radiative cooling technologies, PARC’s self-cooling paint combines high cooling performance with ease of application. PARC’s spray-on solution is the first of its kind and represent a significant departure from other more complex radiative cooling schemes. The paint has been field-tested on a variety of surfaces including aluminum, steel, carbon fiber composites and flexible tent canvas. The demonstrated performance is similar to competing technologies based on selective emitters in the sky transparency window and broadband solar reflectors, with a cooling power during daytime in summer on the order of 100 W/m2."
Quotes
  • "Low-Cost Embedded Asset Monitoring Many critical fielded assets are in need of embedded sensing systems for direct high-resolution, real-time monitoring of their health and condition. The challenge is that many such assets are in space-constrained harsh environments. The reliability requirements, weight and cost constraints for such systems to be field deployable at scale are very demanding."
  • "PARC has developed breakthrough low-cost, compact sensing systems and customized algorithms for high-resolution monitoring of 100s to 1000s of multiplexed fiber optic sensors embedded in harsh environment fielded systems. The technology has been demonstrated in demanding energy and infrastructure systems in collaboration with industry leaders. This video explains how PARC led this technology’s application for electric vehicle battery systems under the ARPA-E AMPED program, in a collaboration with LG Chem and General Motors."
Quotes
  • "FIELDS is a truly transformative approach to computer aided design, manufacturing, and engineering where the computer now serves as a collaborating partner to a human designer. Advanced design automation algorithms built into FIELDS’ engines consider manufacturing capabilities early in the design process, and generate several options for engineers to curate and collaboratively refine. "
  • "Applications: Aerospace Defense Automotive Energy production Manufacturing tooling Medical devices Consumer products"
Quotes
  • "Intelligent Conversational Assistants Advances in speech recognition, natural language understanding, and speech synthesis are enabling technologies for building useful conversational agents. Users of technology are becoming habituated to talking to things. The consumer market is exploding with personal assistants and devices that allow voice interactions. The current slate of personal assistants can assist people by, for example, answering questions and helping to schedule appointments. "
  • "PARC’s technology for interactive and collaborative interactions have taken the form of virtual agents for customer service centers, conversational interfaces for multi-function printers, and enterprise intelligent assistants among others"
Quotes
  • "Low-cost distributed sensing of gases for safety, health, maintenance and efficiency Timely and accurate monitoring of gases is critical for many safety, infrastructure, health, maintenance and environmental applications. Technologies currently on the market are too costly, power-hungry, or insensitive for effective distributed deployment. Building on our world-class capabilities in printing and electronics, PARC has developed a sensor system based on low-power electronics and printed transducers to address this need. PARC’s sensors can enable detection of toxic or environmentally harmful gas leaks, monitoring and control of indoor and ambient air quality, and many other solutions."
  • "While PARC’s technology can be adapted to a wide variety of gases, to date our efforts have focused on early detection of methane leaks and indoor CO2 concentration monitoring for HVAC optimization. Methane is the principal component of natural gas, an important part of the global energy supply, yet cost-effective technologies for monitoring upstream, midstream, and downstream leaks are unavailable. "
  • "PARC’s printed CO2 sensors can enable significant energy savings by reducing this waste while maintaining healthy indoor environments."
Quotes
  • "Flexible, custom-designed microfluidic printing technology CoExtrusion (or CoEx) is a PARC technology for creating structured fluid coatings. At the heart of this technology is a custom-designed microfluidic stack that takes two or more input fluids and interdigitates them to create a patterned film. "
  • "PARC has demonstrated two main applications for CoEx so far. The first is printing high-aspect-ratio conductive traces, and the second is creating interdigitated or “striped” battery electrode films for improved rate performance."
Quotes
  • "IIoT System Analytics Reliable Sensors, Accurate Models, Applied Anywhere As systems become more complex, technology suites that allow for reliable, predictive condition-based maintenance are more challenging than ever. Schedule-driven maintenance practices can result in expensive and unnecessary inspections early in a system’s life and are insufficient as the system ages and deteriorates."
  • "What’s more, the systems supporting traditional maintenance practices have limited accuracy, require extensive training and often result in too many false alarms. This is where PARC’s MOXI™ IIoT System Analytics solution comes into play. Applying the principles of physics to enhance AI-based predictive systems to 90%+ accuracy, our diversified, agile and experienced research & development team will work as a hub between existing technology providers, engineers & facilities or maintenance teams to develop a fully integrated suite of technology designed to provide:"
Quotes
  • "High Performance Optoelectronic Laser Device Technology Since the invention of the laser in 1958, these sophisticated devices have continued to revolutionize our lives. In the process, they have contributed to the generation of an enormous list of new applications in the fields of telecommunications, data storage, consumer electronics, spectroscopy, materials processing, bio-photonics, and life sciences. "
  • "PARC has been a major innovator and technology driver for group-III Nitride based materials and prototype device demonstrators. And our scientists have pioneered the development of cutting-edge visible and UV LEDs and lasers, with record-breaking device performances both in vertical and lateral device architectures. "
Quotes
  • "High-Throughput Assembly of Heterogeneous Micro-electronic Systems Conventional micro-electronic manufacturing technologies rely largely on batch-processing to mass produce systems in a cost-effective manner. This approach does not address many applications that require highly customized, micro-scale systems. "
  • "PARC has developed a novel Micro Assembler printer which uses a digital process to rapidly and accurately assemble micro-objects into functional electronic systems. Our Micro Assembler system is analogous to a laser printer which assembles toner particles onto paper, however it provides the precise position control and registration that is necessary for electronic applications."
Quotes
  • "At PARC, our innovation comes to life through our Competencies – a broad range of disciplines in hardware, software, social sciences and design, where PARC scientists and innovators are thought leaders, at the cutting edge of technological innovation."
  • "We bring together experts from across our Competencies for each new project or partnership, so every organization that works with us benefits from truly unique thinking, drawn from a diverse range of capabilities. Explore a Competency to learn more about the PARC people behind it, and for selected case studies and publications."
  • "AI & Human-Machine Collaboration: User Experience Design, Systems Security, System Prognosis and Health Management, Modeling and Simulation of Cyber, Physical Systems, Interactive Machine Learning, Human-Machine Collaboration, Geometric and Spatial Reasoning, Data Science, Conversational Agents, Computer Vision and Image Synthesis"
  • "IoT & Machine Intelligence: Ubiquitous Sensing, Printing for Manufacturing, Optical Sensors, Optical and Mechanical Microsystems, Printed and Hybrid Electronics User Experience Design, Systems Security, System Prognosis and Health Management, Modeling and Simulation of Cyber-Physical Systems, Interactive Machine, Learning, Geometric and Spatial Reasoning, Data Science"
  • "Digital Design & Manufacturing: Electrochemical Energy Systems, Material Deposition Systems, Polymeric and Composite Materials, Printing for Manufacturing Optical and Mechanical Microsystems, Printed and Hybrid Electronics, User Experience Design, Systems Security, System Prognosis and Health Management Modeling and Simulation of Cyber-Physical Systems, Geometric and Spatial Reasoning"
  • "Microsystems & Smart Devices: Ubiquitous Sensing, Electrochemical Energy Systems, Polymeric and Composite Materials, Semiconductor Materials, Printing for Manufacturing, Optical Sensors, Optical and Mechanical Microsystems, Printed and Hybrid Electronics, Large-Area Thin-Film Electronics, Optoelectronic Devices User Experience Design, Systems Security, System Prognosis and Health Management, Interactive Machine Learning, Geometric and Spatial Reasoning"
  • "Novel Printing: Material Deposition Systems, Polymeric and Composite Materials, Printing for Manufacturing, Optical and Mechanical Microsystems, Printed and Hybrid Electronics, Large-Area Thin-Film Electronics, User Experience Design, Geometric and Spatial Reasoning"
  • "Digital Workplace: Printing for Manufacturing, Optical Sensors, User Experience Design, Systems Security, Interactive Machine Learning, Human-Machine, Collaboration, Data Science, Conversational Agents, Computer Vision and Image Synthesis"